Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6119773,distribution half-life,"Following the i.v. dose, ranitidine plasma concentrations fell biexponentially with a distribution half-life of 6.1 +/- 0.9 min and a terminal elimination half-life of 1.9 +/- 0.1 h.",Pharmacokinetic and gastric secretory studies of ranitidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),min,6.1,260,DB00863,Ranitidine
,6119773,terminal elimination half-life,"Following the i.v. dose, ranitidine plasma concentrations fell biexponentially with a distribution half-life of 6.1 +/- 0.9 min and a terminal elimination half-life of 1.9 +/- 0.1 h.",Pharmacokinetic and gastric secretory studies of ranitidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),h,1.9,261,DB00863,Ranitidine
,6119773,volume of distribution,The volume of distribution was 115 +/- 7 1 and the systemic plasma clearance 709 +/- 62 ml/min.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),1,115,262,DB00863,Ranitidine
,6119773,systemic plasma clearance,The volume of distribution was 115 +/- 7 1 and the systemic plasma clearance 709 +/- 62 ml/min.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),[ml] / [min],709,263,DB00863,Ranitidine
,6119773,systemic availability,After 20 mg oral doses the systemic availability was high (88 +/- 10%).,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,88,264,DB00863,Ranitidine
,6119773,Renal excretion,Renal excretion of unchanged ranitidine was between 50 and 70% and a further 1-3% was excreted as desmethylranitidine.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,50 and 70,265,DB00863,Ranitidine
,6119773,Renal excretion,Renal excretion of unchanged ranitidine was between 50 and 70% and a further 1-3% was excreted as desmethylranitidine.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,1-3,266,DB00863,Ranitidine
,3932043,serum protein binding,The serum protein binding of the free acid metabolite of misoprostol was similar in young (81-88%) and elderly (81-89%) people.,Metabolism and pharmacokinetic studies of misoprostol. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932043/),%,81-88,993,DB00863,Ranitidine
,3932043,serum protein binding,The serum protein binding of the free acid metabolite of misoprostol was similar in young (81-88%) and elderly (81-89%) people.,Metabolism and pharmacokinetic studies of misoprostol. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932043/),%,81-89,994,DB00863,Ranitidine
,3792438,peak plasma oxaprozin concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[μg] / [ml],86,1264,DB00863,Ranitidine
,3792438,volume of distribution,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[l] / [kg],0.23,1265,DB00863,Ranitidine
,3792438,time of peak concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,3.7,1266,DB00863,Ranitidine
,3792438,elimination half-life,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,54,1267,DB00863,Ranitidine
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.047,1268,DB00863,Ranitidine
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.059,1269,DB00863,Ranitidine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],105,2145,DB00863,Ranitidine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[h·μg] / [l],111,2146,DB00863,Ranitidine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[h·μg] / [l],211,2147,DB00863,Ranitidine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],33,2148,DB00863,Ranitidine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],39,2149,DB00863,Ranitidine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],76,2150,DB00863,Ranitidine
,1527233,oral clearance,"No significant difference in adinazolam oral clearance (1,149 vs. 1,135 ml/hr/kg) was noted between treatments (A vs. B, respectively).",Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527233/),[ml] / [h·kg],"1,149",4168,DB00863,Ranitidine
,1527233,oral clearance,"No significant difference in adinazolam oral clearance (1,149 vs. 1,135 ml/hr/kg) was noted between treatments (A vs. B, respectively).",Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527233/),[ml] / [h·kg],"1,135",4169,DB00863,Ranitidine
,1527233,renal clearance,"Furthermore, the renal clearance of NDMAD (196 vs. 198 ml/min) and the cumulative urinary excretion of NDMAD (% dose; 61.2 vs. 62.3) were not significantly different.",Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527233/),[ml] / [min],196,4170,DB00863,Ranitidine
,1527233,renal clearance,"Furthermore, the renal clearance of NDMAD (196 vs. 198 ml/min) and the cumulative urinary excretion of NDMAD (% dose; 61.2 vs. 62.3) were not significantly different.",Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527233/),[ml] / [min],198,4171,DB00863,Ranitidine
,1527233,% dose,"Furthermore, the renal clearance of NDMAD (196 vs. 198 ml/min) and the cumulative urinary excretion of NDMAD (% dose; 61.2 vs. 62.3) were not significantly different.",Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527233/),,61.2,4172,DB00863,Ranitidine
,1527233,% dose,"Furthermore, the renal clearance of NDMAD (196 vs. 198 ml/min) and the cumulative urinary excretion of NDMAD (% dose; 61.2 vs. 62.3) were not significantly different.",Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527233/),,62.3,4173,DB00863,Ranitidine
,9602950,elimination half-life,"Mean +/- 1 standard deviation elimination half-life was 6.61 +/- 2.75 hours, and 41.5 +/- 22.2% of the single dose was eliminated in urine within 24 hours.",Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9602950/),h,6.61,5668,DB00863,Ranitidine
,9131542,Plasma concentrations,Plasma concentrations of ranitidine HCl declined from a mean of 5175 ng/mL at 5 min to 37 ng/mL at 720 min after i.v. administration.,Plasma pharmacokinetics of ranitidine HCl in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[ng] / [ml],5175,5725,DB00863,Ranitidine
,9131542,Plasma concentrations,Plasma concentrations of ranitidine HCl declined from a mean of 5175 ng/mL at 5 min to 37 ng/mL at 720 min after i.v. administration.,Plasma pharmacokinetics of ranitidine HCl in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[ng] / [ml],37,5726,DB00863,Ranitidine
,9131542,apparent volume of distribution (Vdss),"Mean values for model-independent values calculated from the last quantifiable time point were: apparent volume of distribution (Vdss) = 1.07 L/kg; area under the curve (AUC) = 231,000 ng.min/mL: area under the moment curve (AUMC) = 26,900,000 ng.min2/mL; mean residence time (MRT) = 113 min; and clearance (Cl) = 9.8 mL/min.kg.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[l] / [kg],1.07,5727,DB00863,Ranitidine
,9131542,area under the curve (AUC),"Mean values for model-independent values calculated from the last quantifiable time point were: apparent volume of distribution (Vdss) = 1.07 L/kg; area under the curve (AUC) = 231,000 ng.min/mL: area under the moment curve (AUMC) = 26,900,000 ng.min2/mL; mean residence time (MRT) = 113 min; and clearance (Cl) = 9.8 mL/min.kg.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[min·ng] / [ml],"231,000",5728,DB00863,Ranitidine
,9131542,area under the moment curve (AUMC),"Mean values for model-independent values calculated from the last quantifiable time point were: apparent volume of distribution (Vdss) = 1.07 L/kg; area under the curve (AUC) = 231,000 ng.min/mL: area under the moment curve (AUMC) = 26,900,000 ng.min2/mL; mean residence time (MRT) = 113 min; and clearance (Cl) = 9.8 mL/min.kg.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[min2·ng] / [ml],"26,900,000",5729,DB00863,Ranitidine
,9131542,mean residence time (MRT),"Mean values for model-independent values calculated from the last quantifiable time point were: apparent volume of distribution (Vdss) = 1.07 L/kg; area under the curve (AUC) = 231,000 ng.min/mL: area under the moment curve (AUMC) = 26,900,000 ng.min2/mL; mean residence time (MRT) = 113 min; and clearance (Cl) = 9.8 mL/min.kg.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),min,113,5730,DB00863,Ranitidine
,9131542,clearance (Cl),"Mean values for model-independent values calculated from the last quantifiable time point were: apparent volume of distribution (Vdss) = 1.07 L/kg; area under the curve (AUC) = 231,000 ng.min/mL: area under the moment curve (AUMC) = 26,900,000 ng.min2/mL; mean residence time (MRT) = 113 min; and clearance (Cl) = 9.8 mL/min.kg.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[ml] / [kg·min],9.8,5731,DB00863,Ranitidine
,9131542,AUC,"Mean values of pharmacokinetic values from the p.o. study include: AUC = 59,900 ng x min/mL; AUMC = 10,600,000 ng x min2/mL; mean absorption time (MAT) = 58.9 min: Tmax = 99.2 min; Cmax = 237 ng/mL: and F = 27%.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[min·ng] / [ml],"59,900",5732,DB00863,Ranitidine
,9131542,AUMC,"Mean values of pharmacokinetic values from the p.o. study include: AUC = 59,900 ng x min/mL; AUMC = 10,600,000 ng x min2/mL; mean absorption time (MAT) = 58.9 min: Tmax = 99.2 min; Cmax = 237 ng/mL: and F = 27%.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[min2·ng] / [ml],"10,600,000",5733,DB00863,Ranitidine
,9131542,mean absorption time (MAT),"Mean values of pharmacokinetic values from the p.o. study include: AUC = 59,900 ng x min/mL; AUMC = 10,600,000 ng x min2/mL; mean absorption time (MAT) = 58.9 min: Tmax = 99.2 min; Cmax = 237 ng/mL: and F = 27%.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),min,58.9,5734,DB00863,Ranitidine
,9131542,Tmax,"Mean values of pharmacokinetic values from the p.o. study include: AUC = 59,900 ng x min/mL; AUMC = 10,600,000 ng x min2/mL; mean absorption time (MAT) = 58.9 min: Tmax = 99.2 min; Cmax = 237 ng/mL: and F = 27%.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),min,99.2,5735,DB00863,Ranitidine
,9131542,Cmax,"Mean values of pharmacokinetic values from the p.o. study include: AUC = 59,900 ng x min/mL; AUMC = 10,600,000 ng x min2/mL; mean absorption time (MAT) = 58.9 min: Tmax = 99.2 min; Cmax = 237 ng/mL: and F = 27%.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),[ng] / [ml],237,5736,DB00863,Ranitidine
,9131542,F,"Mean values of pharmacokinetic values from the p.o. study include: AUC = 59,900 ng x min/mL; AUMC = 10,600,000 ng x min2/mL; mean absorption time (MAT) = 58.9 min: Tmax = 99.2 min; Cmax = 237 ng/mL: and F = 27%.",Plasma pharmacokinetics of ranitidine HCl in adult horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131542/),%,27,5737,DB00863,Ranitidine
,2903807,t 1/2,"All 'old' and 'new' H2-receptor blockers are eliminated relatively rapidly (t 1/2 ranges from 1.5 to 4 hours), mainly by the renal route (glomerular filtration and tubular secretion).",Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903807/),h,1.5 to 4,6283,DB00863,Ranitidine
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1796,6425,DB00863,Ranitidine
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1258,6426,DB00863,Ranitidine
,2979275,area under the curve,"In the chronic dosing study, the area under the curve for metoprolol was also significantly higher on cimetidine (1796 ng h/ml; P less than 0.001) whereas the area under the curve on ranitidine (1258 ng h/ml) was comparable to that on placebo (1183 ng h/ml).",The effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979275/),[h·ng] / [ml],1183,6427,DB00863,Ranitidine
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,5.7,8319,DB00863,Ranitidine
,6322709,elimination half-life,"Cimetidine, 1,200 mg/day, significantly decreased theophylline clearance by 36% (range, 22% to 49%) and increased the mean elimination half-life from 5.7 hours (control) to 9.2 hours.",Inhibition of theophylline clearance by cimetidine but not ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322709/),h,9.2,8320,DB00863,Ranitidine
,1425718,peak serum levels,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),[mg] / [l],9.1,9020,DB00863,Ranitidine
,1425718,elimination half-life,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),h,7.2,9021,DB00863,Ranitidine
,1425718,area under the curve,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),[h·mg] / [l],116.9,9022,DB00863,Ranitidine
,8854394,plasma concentration,"Ranitidine plasma concentration increased with time, reaching a maximum of (mean +/- SEM) 484 +/- 34 ng/ml in 2.7 +/- 0.2 h.",Pharmacokinetics of oral ranitidine in Mexicans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8854394/),[ng] / [ml],484,11163,DB00863,Ranitidine
,8854394,terminal half-life,Plasma levels then decayed with a terminal half-life of 4.8 +/- 0.3 h.,Pharmacokinetics of oral ranitidine in Mexicans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8854394/),h,4.8,11164,DB00863,Ranitidine
,8854394,area under the plasma concentration against time curve,The area under the plasma concentration against time curve was 2440 +/- 126 ngh/ml.,Pharmacokinetics of oral ranitidine in Mexicans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8854394/),[ngh] / [ml],2440,11165,DB00863,Ranitidine
,2933205,steady-state plasma concentration,Cimetidine significantly increased the mean (+/- SD) steady-state plasma concentration of midazolam from 56.7 +/- 7.8 to 71.3 +/- 19.6 ng/ml (P = 0.004).,Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],56.7,12601,DB00863,Ranitidine
,2933205,steady-state plasma concentration,Cimetidine significantly increased the mean (+/- SD) steady-state plasma concentration of midazolam from 56.7 +/- 7.8 to 71.3 +/- 19.6 ng/ml (P = 0.004).,Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],71.3,12602,DB00863,Ranitidine
,2933205,steady-state midazolam concentration,"In contrast, the steady-state midazolam concentration after ranitidine dosing (61.8 +/- 6.8 ng/ml) did not differ significantly from that after placebo.",Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],61.8,12603,DB00863,Ranitidine
,8424424,integrated 4-h plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[h·mg] / [dl],27.8,14560,DB00863,Ranitidine
,8424424,integrated 4-h plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[h·mg] / [dl],32.4,14561,DB00863,Ranitidine
,8424424,peak plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[mg] / [dl],18.0,14562,DB00863,Ranitidine
,8424424,peak plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[mg] / [dl],21.1,14563,DB00863,Ranitidine
,8424424,time to peak,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),min,43,14564,DB00863,Ranitidine
,8424424,time to peak,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),min,40,14565,DB00863,Ranitidine
,6125203,terminal half-life,2 Oral ranitidine showed a terminal half-life of about 2 h 25 min.,Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125203/),h,2,15028,DB00863,Ranitidine
,6125203,terminal half-life,2 Oral ranitidine showed a terminal half-life of about 2 h 25 min.,Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125203/),min,25,15029,DB00863,Ranitidine
,6125203,Maximal plasma level,"Maximal plasma level was about 240 ng/ml for a 100 mg dose, and occurred about 1 h after dose.",Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125203/),[ng] / [ml],240,15030,DB00863,Ranitidine
,6125203,plasma concentrations,"Mean ranitidine plasma concentrations producing 50 and 80% inhibition of acid secretion were 73 and 180 ng/ml, respectively, with great inter-individual variability.",Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125203/),[ng] / [ml],73,15031,DB00863,Ranitidine
,6125203,plasma concentrations,"Mean ranitidine plasma concentrations producing 50 and 80% inhibition of acid secretion were 73 and 180 ng/ml, respectively, with great inter-individual variability.",Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125203/),[ng] / [ml],180,15032,DB00863,Ranitidine
,6125203,IC50,"150 and 200 mg ranitidine oral doses maintained IC50 for at least 4.5 and 5.5 h, respectively.",Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125203/),h,4.5,15033,DB00863,Ranitidine
,6125203,IC50,"150 and 200 mg ranitidine oral doses maintained IC50 for at least 4.5 and 5.5 h, respectively.",Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125203/),h,5.5,15034,DB00863,Ranitidine
,6299642,Elimination t 1/2,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),h,2,16380,DB00863,Ranitidine
,6299642,plasma clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],10.4,16381,DB00863,Ranitidine
,6299642,plasma clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],7.2,16382,DB00863,Ranitidine
,6299642,renal clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],10.4,16383,DB00863,Ranitidine
,6299642,hepatic clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],10.4,16384,DB00863,Ranitidine
,6299642,volume of distribution,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[l] / [kg],1.82,16385,DB00863,Ranitidine
,6299642,t 1/2,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),h,2.7,16386,DB00863,Ranitidine
,6299642,bioavailability,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),%,52,16387,DB00863,Ranitidine
,6299642,cumulative urinary excretion,The average cumulative urinary excretion of ranitidine as percent of dose was 69.4 +/- 6.1% and 26.7 +/- 7.2% after intravenous and oral doses.,Ranitidine bioavailability and kinetics in normal male subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),%,69.4,16388,DB00863,Ranitidine
,6299642,cumulative urinary excretion,The average cumulative urinary excretion of ranitidine as percent of dose was 69.4 +/- 6.1% and 26.7 +/- 7.2% after intravenous and oral doses.,Ranitidine bioavailability and kinetics in normal male subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),%,26.7,16389,DB00863,Ranitidine
,6271798,elimination half-life,It was found that the elimination half-life of ranitidine ranged from 110-246 min.,Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271798/),min,110-246,17147,DB00863,Ranitidine
,6271798,renal clearance,The mean renal clearance of ranitidine in these four volunteers was 512 ml/min.,Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271798/),[ml] / [min],512,17148,DB00863,Ranitidine
,3700684,peak plasma concentrations,"After oral administration, peak plasma concentrations of 378-808 ng/mL were obtained in two to six hours.",Pharmacokinetics of ranitidine in patients with renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700684/),[ng] / [ml],378-808,17998,DB00863,Ranitidine
,3700684,elimination half-life,"The elimination half-life following oral administration was 8.5 +/- 2.8 hours (standard deviation [SD]), and the bioavailability of ranitidine was 43.3% +/- 10.5%.",Pharmacokinetics of ranitidine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700684/),h,8.5,17999,DB00863,Ranitidine
,3700684,bioavailability,"The elimination half-life following oral administration was 8.5 +/- 2.8 hours (standard deviation [SD]), and the bioavailability of ranitidine was 43.3% +/- 10.5%.",Pharmacokinetics of ranitidine in patients with renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700684/),%,43.3,18000,DB00863,Ranitidine
,3700684,elimination half-life,"After IV administration, the elimination half-life, plasma clearance, renal clearance, and volume of distribution were 7.0 +/- 1.0 hours, 170 +/- 38 mL/min, 36.0 +/- 25.0 mL/min, and 1.3 +/- 0.4 L/kg, respectively.",Pharmacokinetics of ranitidine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700684/),h,7.0,18001,DB00863,Ranitidine
,3700684,plasma clearance,"After IV administration, the elimination half-life, plasma clearance, renal clearance, and volume of distribution were 7.0 +/- 1.0 hours, 170 +/- 38 mL/min, 36.0 +/- 25.0 mL/min, and 1.3 +/- 0.4 L/kg, respectively.",Pharmacokinetics of ranitidine in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700684/),[ml] / [min],170,18002,DB00863,Ranitidine
,3700684,renal clearance,"After IV administration, the elimination half-life, plasma clearance, renal clearance, and volume of distribution were 7.0 +/- 1.0 hours, 170 +/- 38 mL/min, 36.0 +/- 25.0 mL/min, and 1.3 +/- 0.4 L/kg, respectively.",Pharmacokinetics of ranitidine in patients with renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700684/),[ml] / [min],170,18003,DB00863,Ranitidine
,3700684,volume of distribution,"After IV administration, the elimination half-life, plasma clearance, renal clearance, and volume of distribution were 7.0 +/- 1.0 hours, 170 +/- 38 mL/min, 36.0 +/- 25.0 mL/min, and 1.3 +/- 0.4 L/kg, respectively.",Pharmacokinetics of ranitidine in patients with renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700684/),[l] / [kg],1.3,18004,DB00863,Ranitidine
,16416668,distribution volume,"Statistically significant differences were noted in the distribution volume (4.00 +/- 1.11 L/kg in G1, vs 2.15 +/- 1.12 L/kg in G3) of the drug.",Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416668/),[l] / [kg],4.00,18532,DB00863,Ranitidine
,16416668,distribution volume,"Statistically significant differences were noted in the distribution volume (4.00 +/- 1.11 L/kg in G1, vs 2.15 +/- 1.12 L/kg in G3) of the drug.",Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416668/),[l] / [kg],2.15,18533,DB00863,Ranitidine
,16416668,Clearance,Clearance was faster among the G1 (1.11 +/- 0.12 mL/hr) group compared to the G3 group (0.58 +/- 0.19 mL/hr).,Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416668/),[ml] / [h],1.11,18534,DB00863,Ranitidine
,16416668,Clearance,Clearance was faster among the G1 (1.11 +/- 0.12 mL/hr) group compared to the G3 group (0.58 +/- 0.19 mL/hr).,Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416668/),[ml] / [h],0.58,18535,DB00863,Ranitidine
,22607579,t (max),"Median t (max) and t (½) for the 100 mg dose were about 1 and 7 h, respectively, and the pharmacokinetics were dose-proportional.","Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22607579/),h,1,20280,DB00863,Ranitidine
,22607579,t (½),"Median t (max) and t (½) for the 100 mg dose were about 1 and 7 h, respectively, and the pharmacokinetics were dose-proportional.","Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22607579/),h,7,20281,DB00863,Ranitidine
,2614701,area under the plasma concentration-time curve from time 0 to 12 h (AUC0-12),"There were great variations in the plasma concentration-time profiles among subjects; for example, the area under the plasma concentration-time curve from time 0 to 12 h (AUC0-12) varied from 1905 to 5672 micrograms.h/mL.",Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614701/),[h·μg] / [ml],1905 to 5672,20337,DB00863,Ranitidine
,1418073,relative bioavailability,The relative bioavailability of the ranitidine effervescent tablet was 99% compared to the dispersible tablet.,[Bioequivalence and bioavailability after single administration of effervescent ranitidine tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418073/),%,99,21525,DB00863,Ranitidine
,1418073,Cmax ratio,The mean of the Cmax ratio was 95%.,[Bioequivalence and bioavailability after single administration of effervescent ranitidine tablets]. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418073/),%,95,21526,DB00863,Ranitidine
,3768247,apparent oral clearance,"After cimetidine pretreatment there was a significant reduction in the apparent oral clearance of quinine, from 0.182 +/- 0.063 (mean +/- s.d.) to 0.133 +/- 0.055 1 h-1 kg-1 (P less than 0.05).",Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),[1] / [h·kg],0.182,21822,DB00863,Ranitidine
,3768247,apparent oral clearance,"After cimetidine pretreatment there was a significant reduction in the apparent oral clearance of quinine, from 0.182 +/- 0.063 (mean +/- s.d.) to 0.133 +/- 0.055 1 h-1 kg-1 (P less than 0.05).",Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),[1] / [h·kg],0.133,21823,DB00863,Ranitidine
,3768247,elimination half-life,This was reflected in a 49% (range 17 to 90%) increase in the mean elimination half-life from 7.6 +/- 1.3 to 11.3 +/- 3.7 h (P less than 0.05).,Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),h,7.6,21824,DB00863,Ranitidine
,3768247,elimination half-life,This was reflected in a 49% (range 17 to 90%) increase in the mean elimination half-life from 7.6 +/- 1.3 to 11.3 +/- 3.7 h (P less than 0.05).,Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768247/),h,11.3,21825,DB00863,Ranitidine
,11862275,BACs,"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],15.2,24781,DB00863,Ranitidine
,11862275,BACs,"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],27,24782,DB00863,Ranitidine
,11862275,C(max),"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],13,24783,DB00863,Ranitidine
,11862275,C(max),"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],26,24784,DB00863,Ranitidine
less,1409403,relative bioavailability,The relative bioavailability after cecal administration was less than 15% of that observed after administration into the stomach or jejunum.,Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409403/),%,15,26541,DB00863,Ranitidine
,26403509,MTD,MTD of LY with pemetrexed/carboplatin was 40 mg.,"A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26403509/),mg,40,27239,DB00863,Ranitidine
,1981019,maximum plasma concentrations,"On treatment with tertatolol alone, maximum plasma concentrations were 123.7 +/- 32.4 ng/ml (mean +/- SD) and were reached after 1.95 +/- 1.77 hours.",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[ng] / [ml],123.7,27380,DB00863,Ranitidine
,1981019,elimination half-life,The tertatolol elimination half-life was 9.0 +/- 7.1 hours.,Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),h,9.0,27381,DB00863,Ranitidine
,1981019,maximum plasma levels,"Rifampicin, however, decreased the maximum plasma levels of tertatolol to 80.6 +/- 18.5 ng/ml and markedly shortened the elimination half-life to 3.4 +/- 2.6 hours (p less than 0.01 compared with tertatolol alone).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[ng] / [ml],80.6,27382,DB00863,Ranitidine
,1981019,elimination half-life,"Rifampicin, however, decreased the maximum plasma levels of tertatolol to 80.6 +/- 18.5 ng/ml and markedly shortened the elimination half-life to 3.4 +/- 2.6 hours (p less than 0.01 compared with tertatolol alone).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),h,3.4,27383,DB00863,Ranitidine
,1981019,heart rate,"Twenty-four hours after administration, the heart rate in those patients on tertatolol alone (68 +/- 6 beats/min) was lower than in those on tertatolol plus rifampicin (74 +/- 7 beats/min).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[beats] / [min],68,27384,DB00863,Ranitidine
,1981019,heart rate,"Twenty-four hours after administration, the heart rate in those patients on tertatolol alone (68 +/- 6 beats/min) was lower than in those on tertatolol plus rifampicin (74 +/- 7 beats/min).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[beats] / [min],74,27385,DB00863,Ranitidine
,6148361,plasma clearance,"The mean (+/- S.D.) plasma clearance by the spectrophotometric method was 7.48 +/- 2.07 (control), 7.15 +/- 3.07 (ranitidine), and 6.88 +/- 1.35 ml/min/kg (cimetidine).",Lack of effect of histamine H2-receptor antagonists on indocyanine green disposition measured by two methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148361/),[ml] / [kg·min],7.48,27879,DB00863,Ranitidine
,6148361,plasma clearance,"The mean (+/- S.D.) plasma clearance by the spectrophotometric method was 7.48 +/- 2.07 (control), 7.15 +/- 3.07 (ranitidine), and 6.88 +/- 1.35 ml/min/kg (cimetidine).",Lack of effect of histamine H2-receptor antagonists on indocyanine green disposition measured by two methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148361/),[ml] / [kg·min],7.15,27880,DB00863,Ranitidine
,6148361,plasma clearance,"The mean (+/- S.D.) plasma clearance by the spectrophotometric method was 7.48 +/- 2.07 (control), 7.15 +/- 3.07 (ranitidine), and 6.88 +/- 1.35 ml/min/kg (cimetidine).",Lack of effect of histamine H2-receptor antagonists on indocyanine green disposition measured by two methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148361/),[ml] / [kg·min],6.88,27881,DB00863,Ranitidine
,7961108,half life,Pharmacokinetic studies performed using high-performance liquid chromatography demonstrated that plasma concentrations of paclitaxel increased during the 24-h infusion and declined immediately upon cessation of the infusion with a half life of 13.1-24.6 h (75-180 mg/m2).,Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961108/),h,13.1-24.6,29930,DB00863,Ranitidine
,4041335,distribution half-life,The mean (+/- s.e. mean) distribution half-life was 9.42 (+/- 1.04) min.,Pharmacokinetics of ranitidine in quadriplegics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041335/),min,9.42,31076,DB00863,Ranitidine
,4041335,terminal plasma elimination half-life,"The terminal plasma elimination half-life 1.79 (+/- 0.12) h, the volume of distribution 103 (+/- 17) litres and total body clearance 663 (+/- 86) ml/min.",Pharmacokinetics of ranitidine in quadriplegics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041335/),h,1.79,31077,DB00863,Ranitidine
,4041335,volume of distribution,"The terminal plasma elimination half-life 1.79 (+/- 0.12) h, the volume of distribution 103 (+/- 17) litres and total body clearance 663 (+/- 86) ml/min.",Pharmacokinetics of ranitidine in quadriplegics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041335/),l,103,31078,DB00863,Ranitidine
,4041335,total body clearance,"The terminal plasma elimination half-life 1.79 (+/- 0.12) h, the volume of distribution 103 (+/- 17) litres and total body clearance 663 (+/- 86) ml/min.",Pharmacokinetics of ranitidine in quadriplegics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041335/),[ml] / [min],663,31079,DB00863,Ranitidine
,6125204,distribution half-life (t 1/2 alpha),The mean (+/- s.d.) distribution half-life (t 1/2 alpha) was 6.6 +/- 1.6 min; plasma half-life (t 1/2 beta) was 1.7 +/- 0.2 h; the volume of distribution (V) was 96 +/- 9 1; total body clearance (CL) was 647 +/- 94 ml/min and renal clearance (CLR) 520 +/- 123 ml/min.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),min,6.6,31901,DB00863,Ranitidine
,6125204,plasma half-life (t 1/2 beta),The mean (+/- s.d.) distribution half-life (t 1/2 alpha) was 6.6 +/- 1.6 min; plasma half-life (t 1/2 beta) was 1.7 +/- 0.2 h; the volume of distribution (V) was 96 +/- 9 1; total body clearance (CL) was 647 +/- 94 ml/min and renal clearance (CLR) 520 +/- 123 ml/min.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),h,1.7,31902,DB00863,Ranitidine
,6125204,volume of distribution (V),The mean (+/- s.d.) distribution half-life (t 1/2 alpha) was 6.6 +/- 1.6 min; plasma half-life (t 1/2 beta) was 1.7 +/- 0.2 h; the volume of distribution (V) was 96 +/- 9 1; total body clearance (CL) was 647 +/- 94 ml/min and renal clearance (CLR) 520 +/- 123 ml/min.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),1,96,31903,DB00863,Ranitidine
,6125204,total body clearance (CL),The mean (+/- s.d.) distribution half-life (t 1/2 alpha) was 6.6 +/- 1.6 min; plasma half-life (t 1/2 beta) was 1.7 +/- 0.2 h; the volume of distribution (V) was 96 +/- 9 1; total body clearance (CL) was 647 +/- 94 ml/min and renal clearance (CLR) 520 +/- 123 ml/min.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),[ml] / [min],647,31904,DB00863,Ranitidine
,6125204,renal clearance (CLR),The mean (+/- s.d.) distribution half-life (t 1/2 alpha) was 6.6 +/- 1.6 min; plasma half-life (t 1/2 beta) was 1.7 +/- 0.2 h; the volume of distribution (V) was 96 +/- 9 1; total body clearance (CL) was 647 +/- 94 ml/min and renal clearance (CLR) 520 +/- 123 ml/min.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),[ml] / [min],520,31905,DB00863,Ranitidine
,6125204,absolute availability,The absolute availability was 60 +/- 17%.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),%,60,31906,DB00863,Ranitidine
,6125204,plasma half-life (t 1/2),The plasma half-life (t 1/2) of 2.3 +/- 0.4 h was significantly longer (P less than 0.05) after oral than after i.v. administration.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),h,2.3,31907,DB00863,Ranitidine
,6125204,Renal excretion,4 Renal excretion of unchanged ranitidine accounted for 79 +/- 9% of the dose after i.v. administration and for 27 +/- 7% after oral administration.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),,79,31908,DB00863,Ranitidine
,6125204,Renal excretion,4 Renal excretion of unchanged ranitidine accounted for 79 +/- 9% of the dose after i.v. administration and for 27 +/- 7% after oral administration.,Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6125204/),%,27,31909,DB00863,Ranitidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.7,31995,DB00863,Ranitidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],9.0,31996,DB00863,Ranitidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.5,31997,DB00863,Ranitidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.1,31998,DB00863,Ranitidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.6,31999,DB00863,Ranitidine
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.2,32000,DB00863,Ranitidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,19.6,32001,DB00863,Ranitidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,26.2,32002,DB00863,Ranitidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,13.3,32003,DB00863,Ranitidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,18.4,32004,DB00863,Ranitidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,13.2,32005,DB00863,Ranitidine
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,19.0,32006,DB00863,Ranitidine
,9269495,permeation rate constant,"For all four formulations, this analysis suggests absorption was permeation-rate limited, where ranitidine exhibited a low permeation rate constant of 0.01/min.","In vitro-in vivo relationships of several ""immediate"" release tablets containing a low permeability drug. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269495/),1/[min],0.01,32212,DB00863,Ranitidine
,16278926,Cmax,"Values (mean+/-SEM) were: Cmax 528.85+/-25.34 and 563.03+/-33.25 ng/ml, tmax 2.76+/-0.19 and 2.79+/-0.18 h, and AUC12 h 2694.94+/-99.50 and 2648.51+/-133.38 ng.h/ml, for Azantac or Midaven, respectively.",Comparative bioavailability of two oral formulations of ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278926/),[ng] / [ml],528.85,32703,DB00863,Ranitidine
,16278926,Cmax,"Values (mean+/-SEM) were: Cmax 528.85+/-25.34 and 563.03+/-33.25 ng/ml, tmax 2.76+/-0.19 and 2.79+/-0.18 h, and AUC12 h 2694.94+/-99.50 and 2648.51+/-133.38 ng.h/ml, for Azantac or Midaven, respectively.",Comparative bioavailability of two oral formulations of ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278926/),[ng] / [ml],563.03,32704,DB00863,Ranitidine
,16278926,tmax,"Values (mean+/-SEM) were: Cmax 528.85+/-25.34 and 563.03+/-33.25 ng/ml, tmax 2.76+/-0.19 and 2.79+/-0.18 h, and AUC12 h 2694.94+/-99.50 and 2648.51+/-133.38 ng.h/ml, for Azantac or Midaven, respectively.",Comparative bioavailability of two oral formulations of ranitidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278926/),h,2.76,32705,DB00863,Ranitidine
,16278926,tmax,"Values (mean+/-SEM) were: Cmax 528.85+/-25.34 and 563.03+/-33.25 ng/ml, tmax 2.76+/-0.19 and 2.79+/-0.18 h, and AUC12 h 2694.94+/-99.50 and 2648.51+/-133.38 ng.h/ml, for Azantac or Midaven, respectively.",Comparative bioavailability of two oral formulations of ranitidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278926/),h,2.79,32706,DB00863,Ranitidine
,16278926,AUC12 h,"Values (mean+/-SEM) were: Cmax 528.85+/-25.34 and 563.03+/-33.25 ng/ml, tmax 2.76+/-0.19 and 2.79+/-0.18 h, and AUC12 h 2694.94+/-99.50 and 2648.51+/-133.38 ng.h/ml, for Azantac or Midaven, respectively.",Comparative bioavailability of two oral formulations of ranitidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278926/),[h·ng] / [ml],2694.94,32707,DB00863,Ranitidine
,16278926,AUC12 h,"Values (mean+/-SEM) were: Cmax 528.85+/-25.34 and 563.03+/-33.25 ng/ml, tmax 2.76+/-0.19 and 2.79+/-0.18 h, and AUC12 h 2694.94+/-99.50 and 2648.51+/-133.38 ng.h/ml, for Azantac or Midaven, respectively.",Comparative bioavailability of two oral formulations of ranitidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278926/),[h·ng] / [ml],2648.51,32708,DB00863,Ranitidine
,1889712,urinary,"When predosed with placebo, the median integrated 8-hour plasma bismuth concentration was significantly greater after dosing with De-Noltabs than after dosing with either Pepto-Bismol or Roter (61, 8, and 8 ng.h/mL, respectively), with a similar trend for 8-hour median urinary bismuth excretion (213, 40, and 6 micrograms, respectively).",The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889712/),μg,213,34923,DB00863,Ranitidine
,1889712,urinary,"When predosed with placebo, the median integrated 8-hour plasma bismuth concentration was significantly greater after dosing with De-Noltabs than after dosing with either Pepto-Bismol or Roter (61, 8, and 8 ng.h/mL, respectively), with a similar trend for 8-hour median urinary bismuth excretion (213, 40, and 6 micrograms, respectively).",The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889712/),μg,40,34924,DB00863,Ranitidine
,1889712,urinary,"When predosed with placebo, the median integrated 8-hour plasma bismuth concentration was significantly greater after dosing with De-Noltabs than after dosing with either Pepto-Bismol or Roter (61, 8, and 8 ng.h/mL, respectively), with a similar trend for 8-hour median urinary bismuth excretion (213, 40, and 6 micrograms, respectively).",The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889712/),μg,6,34925,DB00863,Ranitidine
,1889712,excretion,"When predosed with placebo, the median integrated 8-hour plasma bismuth concentration was significantly greater after dosing with De-Noltabs than after dosing with either Pepto-Bismol or Roter (61, 8, and 8 ng.h/mL, respectively), with a similar trend for 8-hour median urinary bismuth excretion (213, 40, and 6 micrograms, respectively).",The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889712/),μg,213,34926,DB00863,Ranitidine
,1889712,excretion,"When predosed with placebo, the median integrated 8-hour plasma bismuth concentration was significantly greater after dosing with De-Noltabs than after dosing with either Pepto-Bismol or Roter (61, 8, and 8 ng.h/mL, respectively), with a similar trend for 8-hour median urinary bismuth excretion (213, 40, and 6 micrograms, respectively).",The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889712/),μg,40,34927,DB00863,Ranitidine
,1889712,excretion,"When predosed with placebo, the median integrated 8-hour plasma bismuth concentration was significantly greater after dosing with De-Noltabs than after dosing with either Pepto-Bismol or Roter (61, 8, and 8 ng.h/mL, respectively), with a similar trend for 8-hour median urinary bismuth excretion (213, 40, and 6 micrograms, respectively).",The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889712/),μg,6,34928,DB00863,Ranitidine
,1889712,urinary,"When predosed with ranitidine, only after De-Noltab administration were there significant increases in the 8-hour plasma bismuth concentration (147 ng.h/mL), and 8-hour urinary bismuth excretion (686 micrograms).",The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889712/),μg,686,34929,DB00863,Ranitidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],7.76,35040,DB00863,Ranitidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],11.50,35041,DB00863,Ranitidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],73.0,35042,DB00863,Ranitidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],91.5,35043,DB00863,Ranitidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],101,35044,DB00863,Ranitidine
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],123,35045,DB00863,Ranitidine
,9692688,first pass metabolism,"Following food, and with ethanol taken in the form of beer, mean first pass metabolism of ethanol was 58% (range 34-78%).","Omeprazole, ranitidine, and cimetidine have no effect on peak blood ethanol concentrations, first pass metabolism or area under the time-ethanol curve under 'real-life' drinking conditions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692688/),%,58,37226,DB00863,Ranitidine
,22286158,apparent clearance,"A one-compartment model with first order absorption and elimination as the basic structural model appropriately described the data, with an apparent clearance of 56.8 L/h [95% confidence interval (CI) 52.8–60.8 L/h] and an apparent volume of distribution of 2,130 L (95% CI 1,646–2,614 L).",Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286158/),[l] / [h],56.8,37925,DB00863,Ranitidine
,22286158,apparent volume of distribution,"A one-compartment model with first order absorption and elimination as the basic structural model appropriately described the data, with an apparent clearance of 56.8 L/h [95% confidence interval (CI) 52.8–60.8 L/h] and an apparent volume of distribution of 2,130 L (95% CI 1,646–2,614 L).",Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286158/),l,"2,130",37926,DB00863,Ranitidine
,1690458,milk/plasma ratios,The milk/plasma ratios far exceeded the theoretical milk/plasma ratio of 2.0.,Excretion of high concentrations of cimetidine and ranitidine into rat milk and their effects on milk composition and mammary gland nucleic acid content. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1690458/),,2.0,39354,DB00863,Ranitidine
,1690458,milk/plasma ratio,The milk/plasma ratios far exceeded the theoretical milk/plasma ratio of 2.0.,Excretion of high concentrations of cimetidine and ranitidine into rat milk and their effects on milk composition and mammary gland nucleic acid content. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1690458/),,2.0,39355,DB00863,Ranitidine
,1797416,mesor concentration,Cosinor analyses of the mean ranitidine plasma concentration data showed a mesor concentration of 237 ng/mL and amplitude of 76 ng/mL (coefficient of determination [CD] = 0.98).,Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797416/),[ng] / [ml],237,41112,DB00863,Ranitidine
,1797416,amplitude,Cosinor analyses of the mean ranitidine plasma concentration data showed a mesor concentration of 237 ng/mL and amplitude of 76 ng/mL (coefficient of determination [CD] = 0.98).,Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797416/),[ng] / [ml],76,41113,DB00863,Ranitidine
,1797416,plasma concentration,The constant-rate infusion resulted in a mean plasma concentration of 222 +/- 32 ng/mL.,Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797416/),[ng] / [ml],222,41114,DB00863,Ranitidine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.83,43396,DB00863,Ranitidine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.32,43397,DB00863,Ranitidine
,20347037,clearance,"In vivo data correlated with IPK results as clofarabine clearance decreased 61% (20.2-7.80mL/min/kg), upon co-administration with cimetidine in rats.",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [kg·min],20.2-7.80,43398,DB00863,Ranitidine
,14609279,flow rate,"Mobile phase consisting of dibasic potasium phosphate 0.08 M/acetonitrile/methanol/triethylamine 0.05% (89.5:3:7:0.05) pH5 was used at a flow rate of 0.9 ml/min on a C18 column (Nova-Pack, 3,9 x 300 mm, Waters).",Validated HPLC method for the determination of ranitidine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609279/),[ml] / [min],0.9,45561,DB00863,Ranitidine
,1673880,oral bioavailability,The mean oral bioavailability for the H2-antagonists ranges from 50 to 70%.,Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),%,50 to 70,45683,DB00863,Ranitidine
,1673880,terminal half-life,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),h,1 to 3,45684,DB00863,Ranitidine
,1673880,total body clearance,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],24 to 48,45685,DB00863,Ranitidine
,1673880,renal clearances,"Elimination is mainly attributable to renal excretion, with renal clearances ranging from 13.8 to 30 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],13.8 to 30,45686,DB00863,Ranitidine
,7554702,oral bioavailability,"In women, oral bioavailability of alendronate was independent of dose (5 to 80 mg) and averaged (90% confidence interval) 0.76% (0.58, 0.98) when taken with water in the fasting state, followed by a meal 2 hours later.",Studies of the oral bioavailability of alendronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554702/),%,0.76,47621,DB00863,Ranitidine
,7554702,Bioavailability,"Bioavailability was similar in men [0.59%, (0.43, 0.81)].",Studies of the oral bioavailability of alendronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554702/),%,0.59,47622,DB00863,Ranitidine
,7554702,bioavailability,"Black coffee or orange juice alone, when taken with the drug, also reduced bioavailability (approximately 60%).",Studies of the oral bioavailability of alendronate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554702/),%,60,47623,DB00863,Ranitidine
,9754889,recovery,A mean recovery of 9.9% of the drug was realized in the urine in 24 h following ranitidine pretreatment compared to 6.2% of the dose after D5W pretreatment (P < 0.03).,The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754889/),%,9.9,47915,DB00863,Ranitidine
,9754889,recovery,A mean recovery of 9.9% of the drug was realized in the urine in 24 h following ranitidine pretreatment compared to 6.2% of the dose after D5W pretreatment (P < 0.03).,The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754889/),%,6.2,47916,DB00863,Ranitidine
,8323366,elimination half life,"From this model the following mean (SD) measurements wer derived: elimination half life, 207.1 (19.1) minutes; total volume of distribution, 1.52 (0.91) l/kg; and total plasma clearance, 5.02 (0.46) ml/kg/min.",Ranitidine pharmacokinetics in newborn infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8323366/),min,207.1,49997,DB00863,Ranitidine
,8323366,total volume of distribution,"From this model the following mean (SD) measurements wer derived: elimination half life, 207.1 (19.1) minutes; total volume of distribution, 1.52 (0.91) l/kg; and total plasma clearance, 5.02 (0.46) ml/kg/min.",Ranitidine pharmacokinetics in newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8323366/),[l] / [kg],1.52,49998,DB00863,Ranitidine
,8323366,total plasma clearance,"From this model the following mean (SD) measurements wer derived: elimination half life, 207.1 (19.1) minutes; total volume of distribution, 1.52 (0.91) l/kg; and total plasma clearance, 5.02 (0.46) ml/kg/min.",Ranitidine pharmacokinetics in newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8323366/),[ml] / [kg·min],5.02,49999,DB00863,Ranitidine
,3921686,IC50,"The IC50 for H+ secretion was between 50 and 100 ng/ml, and the IC90 between 130 and 150 ng/ml.",Effect of ranitidine on gastric acid hypersecretion in an infant with short bowel syndrome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921686/),[ng] / [ml],50 and 100,50256,DB00863,Ranitidine
,3921686,IC90,"The IC50 for H+ secretion was between 50 and 100 ng/ml, and the IC90 between 130 and 150 ng/ml.",Effect of ranitidine on gastric acid hypersecretion in an infant with short bowel syndrome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921686/),[ng] / [ml],130 and 150,50257,DB00863,Ranitidine
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.29,51051,DB00863,Ranitidine
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.93,51052,DB00863,Ranitidine
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.97,51053,DB00863,Ranitidine
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.26,51054,DB00863,Ranitidine
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.24,51055,DB00863,Ranitidine
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.25,51056,DB00863,Ranitidine
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.140,51057,DB00863,Ranitidine
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.141,51058,DB00863,Ranitidine
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.146,51059,DB00863,Ranitidine
,8835044,serum concentration (Cp),Subjects received extended-release oral theophylline at a constant dosage over 4 weeks to yield a serum concentration (Cp) between 5 and 10 micrograms/mL.,Effect of ranitidine on theophylline metabolism in healthy Koreans living in China. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835044/),[μg] / [ml],5 and 10,51752,DB00863,Ranitidine
,9095337,bioavailability,"Zilascorb(2H) in tablet formulation had a bioavailability of 32%, was quickly absorbed and slowly eliminated.","Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9095337/),%,32,56726,DB00863,Ranitidine
,2262900,steady-state plasma concentrations,Sixteen sheep were administered both cimetidine and ranitidine in random order by a combination of bolus and i.v. infusion to achieve steady-state plasma concentrations of 1000 to 2000 ng/ml.,Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),[ng] / [ml],1000 to 2000,61425,DB00863,Ranitidine
,2262900,renal clearance,Maternal renal clearance of cimetidine (0.51 +/- 0.18 l/min) and ranitidine (0.54 +/- 0.14 l/min) were not correlated with the period of gestation.,Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),[l] / [min],0.51,61426,DB00863,Ranitidine
,2262900,renal clearance,Maternal renal clearance of cimetidine (0.51 +/- 0.18 l/min) and ranitidine (0.54 +/- 0.14 l/min) were not correlated with the period of gestation.,Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),[l] / [min],0.54,61427,DB00863,Ranitidine
,2262900,renal clearance ratios,"Cimetidine/creatinine and ranitidine/creatinine renal clearance ratios were higher than unity being 5.48 +/- 1.91 and 5.65 +/- 1.18, respectively.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,5.48,61428,DB00863,Ranitidine
,2262900,renal clearance ratios,"Cimetidine/creatinine and ranitidine/creatinine renal clearance ratios were higher than unity being 5.48 +/- 1.91 and 5.65 +/- 1.18, respectively.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,5.65,61429,DB00863,Ranitidine
,2262900,renal clearance ratios,"At 80 days, cimetidine/creatinine and ranitidine/creatinine renal clearance ratios (3.0 and 4.4, respectively) were higher than unity and did not increase further during the remainder of gestation.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,3.0,61430,DB00863,Ranitidine
,2262900,renal clearance ratios,"At 80 days, cimetidine/creatinine and ranitidine/creatinine renal clearance ratios (3.0 and 4.4, respectively) were higher than unity and did not increase further during the remainder of gestation.",Ontogeny of fetal renal organic cation excretion: a study with cimetidine and ranitidine during the latter half of gestation in the pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262900/),,4.4,61431,DB00863,Ranitidine
,11151748,clearance,"The dialyzer clearance of ranitidine on PS membrane (67.2 +/- 4.4 ml/min/m2) was significantly higher than that on CP (43.1 +/- 3.8 ml/min/m2, P < 0.001).",Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151748/),[ml] / [m2·min],67.2,61744,DB00863,Ranitidine
,11151748,clearance,"The dialyzer clearance of ranitidine on PS membrane (67.2 +/- 4.4 ml/min/m2) was significantly higher than that on CP (43.1 +/- 3.8 ml/min/m2, P < 0.001).",Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151748/),[ml] / [m2·min],43.1,61745,DB00863,Ranitidine
,11151748,Elimination fraction (EF),Elimination fraction (EF) of the drug during the dialysis with PS was also significantly higher than that with CP (72 +/- 2% versus 44 +/- 3%).,Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151748/),%,72,61746,DB00863,Ranitidine
,11151748,Elimination fraction (EF),Elimination fraction (EF) of the drug during the dialysis with PS was also significantly higher than that with CP (72 +/- 2% versus 44 +/- 3%).,Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151748/),%,44,61747,DB00863,Ranitidine
,11151748,Apparent half-life,Apparent half-life of ranitidine during dialysis with PS (2.9 +/- 0.4 h) was shorter than that with CP (5.1 +/- 0.7 h).,Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151748/),h,2.9,61748,DB00863,Ranitidine
,11151748,Apparent half-life,Apparent half-life of ranitidine during dialysis with PS (2.9 +/- 0.4 h) was shorter than that with CP (5.1 +/- 0.7 h).,Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11151748/),h,5.1,61749,DB00863,Ranitidine
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],16.6,62253,DB00863,Ranitidine
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],19.2,62254,DB00863,Ranitidine
,2760148,extraction recoveries,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),%,99.8,62967,DB00863,Ranitidine
,2760148,extraction recoveries,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),%,30.4,62968,DB00863,Ranitidine
,2760148,extraction recoveries,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),%,74.2,62969,DB00863,Ranitidine
,2760148,extraction recoveries,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),%,80.2,62970,DB00863,Ranitidine
,2760148,detection limits,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),[ng] / [ml],5,62971,DB00863,Ranitidine
,2760148,detection limits,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),[ng] / [ml],15,62972,DB00863,Ranitidine
,2760148,detection limits,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),[ng] / [ml],10,62973,DB00863,Ranitidine
,2760148,detection limits,"The extraction recoveries were 99.8, 30.4, 74.2 and 80.2% and the detection limits were 5, 15, 10 and 4 ng/ml for ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethylranitidine, respectively.",Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760148/),[ng] / [ml],4,62974,DB00863,Ranitidine
,18384065,half-lives,"After ranitidine was orally dosed alone or with DCQD, the half-lives were 1.787 and 3.758 h, while the area under the concentration-time curve (0-12 h) was 28.083 and 9.826 microg/L h, respectively, suggesting that DCQD might significantly affect the pharmacokinetics of ranitidine in rats.",Effect of Da-Cheng-Qi decoction on the pharmacokinetics of ranitidine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384065/),h,1.787,64242,DB00863,Ranitidine
,18384065,half-lives,"After ranitidine was orally dosed alone or with DCQD, the half-lives were 1.787 and 3.758 h, while the area under the concentration-time curve (0-12 h) was 28.083 and 9.826 microg/L h, respectively, suggesting that DCQD might significantly affect the pharmacokinetics of ranitidine in rats.",Effect of Da-Cheng-Qi decoction on the pharmacokinetics of ranitidine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384065/),h,3.758,64243,DB00863,Ranitidine
,18384065,area under the concentration-time curve (0-12 h),"After ranitidine was orally dosed alone or with DCQD, the half-lives were 1.787 and 3.758 h, while the area under the concentration-time curve (0-12 h) was 28.083 and 9.826 microg/L h, respectively, suggesting that DCQD might significantly affect the pharmacokinetics of ranitidine in rats.",Effect of Da-Cheng-Qi decoction on the pharmacokinetics of ranitidine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384065/),[μg] / [h·l],28.083,64244,DB00863,Ranitidine
,18384065,area under the concentration-time curve (0-12 h),"After ranitidine was orally dosed alone or with DCQD, the half-lives were 1.787 and 3.758 h, while the area under the concentration-time curve (0-12 h) was 28.083 and 9.826 microg/L h, respectively, suggesting that DCQD might significantly affect the pharmacokinetics of ranitidine in rats.",Effect of Da-Cheng-Qi decoction on the pharmacokinetics of ranitidine in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384065/),[μg] / [h·l],9.826,64245,DB00863,Ranitidine
,8310710,renal clearance,"Its renal clearance averaged 6.65 ml/min per kg (350% of the creatinine clearance) in all subjects, 74% being due to net tubular secretion.",Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),[ml] / [kg·min],6.65,64883,DB00863,Ranitidine
,8310710,elimination,5. Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0.23 h-1) when administered orally as a non-retarded preparation.,Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),1/[h],2,64884,DB00863,Ranitidine
,8310710,absorption rate constant,5. Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0.23 h-1) when administered orally as a non-retarded preparation.,Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),1/[h],0.23,64885,DB00863,Ranitidine
,6128298,clearance,"In control experiments (no other drug present), antipyrine clearance was 32.5 +/- 0.9 ml per hr.",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],32.5,67082,DB00863,Ranitidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],10.1,67083,DB00863,Ranitidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],5.8,67084,DB00863,Ranitidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],4.5,67085,DB00863,Ranitidine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],3.0,67086,DB00863,Ranitidine
,12604553,maximum concentration of the drug in plasma (C(max)),"Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng.",ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604553/),[ng] / [ml],318,68403,DB00863,Ranitidine
,12604553,half-life,"Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng.",ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604553/),h,5.66,68404,DB00863,Ranitidine
,12604553,area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )),"Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng.",ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604553/),ng,"1,662",68405,DB00863,Ranitidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],547,69199,DB00863,Ranitidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],531,69200,DB00863,Ranitidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],563,69201,DB00863,Ranitidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],529,69202,DB00863,Ranitidine
,8290486,Gastric residence times,"Gastric residence times were 46, 33, and 51 min for Treatments V, Z, and V/Z, respectively.",Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290486/),min,46,74425,DB00863,Ranitidine
,8290486,Gastric residence times,"Gastric residence times were 46, 33, and 51 min for Treatments V, Z, and V/Z, respectively.",Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290486/),min,33,74426,DB00863,Ranitidine
,8290486,Gastric residence times,"Gastric residence times were 46, 33, and 51 min for Treatments V, Z, and V/Z, respectively.",Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8290486/),min,51,74427,DB00863,Ranitidine
,7859806,Cmax,"After the last dose the geometric mean for Cmax for 500 mg bid of GR122311X was 5 ng.g-1, for 1.0 g bid GR122311X it was 12 ng.g-1 and it was 21 ng.g-1 for 240 mg TDB bid.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),[ng] / [g],5,74461,DB00863,Ranitidine
,7859806,Cmax,"After the last dose the geometric mean for Cmax for 500 mg bid of GR122311X was 5 ng.g-1, for 1.0 g bid GR122311X it was 12 ng.g-1 and it was 21 ng.g-1 for 240 mg TDB bid.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),[ng] / [g],12,74462,DB00863,Ranitidine
,7859806,Cmax,"After the last dose the geometric mean for Cmax for 500 mg bid of GR122311X was 5 ng.g-1, for 1.0 g bid GR122311X it was 12 ng.g-1 and it was 21 ng.g-1 for 240 mg TDB bid.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),[ng] / [g],21,74463,DB00863,Ranitidine
,7859806,trough plasma levels,"The corresponding trough plasma levels were 2 ng.g-1, 4 ng.g-1 and 4 ng.g-1, respectively.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),[ng] / [g],2,74464,DB00863,Ranitidine
,7859806,trough plasma levels,"The corresponding trough plasma levels were 2 ng.g-1, 4 ng.g-1 and 4 ng.g-1, respectively.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),[ng] / [g],4,74465,DB00863,Ranitidine
,7859806,AUC,The AUC over a dosing interval after the last dose (AUC tau) were 34 ng.,"Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),ng,34,74466,DB00863,Ranitidine
,7859806,urinary recoveries,"The bismuth urinary recoveries over the last dosing interval (Ae tau) were 97 micrograms, 227 micrograms and 309 micrograms, respectively, which is less than 1% of the administered doses.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),μg,97,74467,DB00863,Ranitidine
,7859806,urinary recoveries,"The bismuth urinary recoveries over the last dosing interval (Ae tau) were 97 micrograms, 227 micrograms and 309 micrograms, respectively, which is less than 1% of the administered doses.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),μg,227,74468,DB00863,Ranitidine
,7859806,urinary recoveries,"The bismuth urinary recoveries over the last dosing interval (Ae tau) were 97 micrograms, 227 micrograms and 309 micrograms, respectively, which is less than 1% of the administered doses.","Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859806/),μg,309,74469,DB00863,Ranitidine
,27412521,half-life elimination of (t1/2el),"Pharmacokinetics of ranitidine had a bi-exponential behavior with a half-life elimination of (t1/2el) 2.79 h, area under curve (AUC) of 1688 ng/mL, volume of distribution (Vd) of 1.44 L/kg, and clearance (Cl) of 5.9 L/kg/h.",Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27412521/),h,2.79,74549,DB00863,Ranitidine
,27412521,area under curve (AUC),"Pharmacokinetics of ranitidine had a bi-exponential behavior with a half-life elimination of (t1/2el) 2.79 h, area under curve (AUC) of 1688 ng/mL, volume of distribution (Vd) of 1.44 L/kg, and clearance (Cl) of 5.9 L/kg/h.",Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27412521/),[ng] / [ml],1688,74550,DB00863,Ranitidine
,27412521,volume of distribution (Vd),"Pharmacokinetics of ranitidine had a bi-exponential behavior with a half-life elimination of (t1/2el) 2.79 h, area under curve (AUC) of 1688 ng/mL, volume of distribution (Vd) of 1.44 L/kg, and clearance (Cl) of 5.9 L/kg/h.",Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27412521/),[l] / [kg],1.44,74551,DB00863,Ranitidine
,27412521,clearance (Cl),"Pharmacokinetics of ranitidine had a bi-exponential behavior with a half-life elimination of (t1/2el) 2.79 h, area under curve (AUC) of 1688 ng/mL, volume of distribution (Vd) of 1.44 L/kg, and clearance (Cl) of 5.9 L/kg/h.",Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27412521/),[l] / [h·kg],5.9,74552,DB00863,Ranitidine
,27412521,plasmatic concentration,The median plasmatic concentration in pre-terms was 1113 ng/mL and 280 ng/mL in full-terms.,Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27412521/),[ng] / [ml],1113,74553,DB00863,Ranitidine
,27412521,plasmatic concentration,The median plasmatic concentration in pre-terms was 1113 ng/mL and 280 ng/mL in full-terms.,Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27412521/),[ng] / [ml],280,74554,DB00863,Ranitidine
,1298048,half-life,"From the single-dose study the calculated half-life, volume of distribution, and clearance were 3.14 +/- 0.61 h, 1.45 +/- 0.42 l/kg, and 0.40 +/- 0.14 l/kg/h for group A and 3.33 +/- 1.08 h, 1.16 +/- 0.20 l/kg, and 0.35 +/- 0.21 l/kg/h, for group B, respectively.",Pharmacokinetics of ranitidine in a homogeneous population of intensive care unit patients during intermittent and continuous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1298048/),h,3.14,74693,DB00863,Ranitidine
,1298048,clearance,"From the single-dose study the calculated half-life, volume of distribution, and clearance were 3.14 +/- 0.61 h, 1.45 +/- 0.42 l/kg, and 0.40 +/- 0.14 l/kg/h for group A and 3.33 +/- 1.08 h, 1.16 +/- 0.20 l/kg, and 0.35 +/- 0.21 l/kg/h, for group B, respectively.",Pharmacokinetics of ranitidine in a homogeneous population of intensive care unit patients during intermittent and continuous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1298048/),[l] / [h·kg],0.40,74694,DB00863,Ranitidine
,1298048,clearance,"From the single-dose study the calculated half-life, volume of distribution, and clearance were 3.14 +/- 0.61 h, 1.45 +/- 0.42 l/kg, and 0.40 +/- 0.14 l/kg/h for group A and 3.33 +/- 1.08 h, 1.16 +/- 0.20 l/kg, and 0.35 +/- 0.21 l/kg/h, for group B, respectively.",Pharmacokinetics of ranitidine in a homogeneous population of intensive care unit patients during intermittent and continuous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1298048/),[l] / [h·kg],0.35,74695,DB00863,Ranitidine
,9430768,Plasma concentrations,Plasma concentrations of ranitidine HCl declined from a mean of 3266 ng/mL at 5 min to 11 ng/mL at 720 min after administration.,Plasma pharmacokinetics of ranitidine HCl in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[ng] / [ml],3266,77846,DB00863,Ranitidine
,9430768,Plasma concentrations,Plasma concentrations of ranitidine HCl declined from a mean of 3266 ng/mL at 5 min to 11 ng/mL at 720 min after administration.,Plasma pharmacokinetics of ranitidine HCl in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[ng] / [ml],11,77847,DB00863,Ranitidine
,9430768,apparent volume of distribution (Vdss),"Mean values for model-independent values were: apparent volume of distribution (Vdss) = 1.46 L/kg; area under the curve (AUC) = 167,442 ng.min/mL; area under the moment curve (AUMC) = 18,068,221 ng.min2/mL; mean residence time (MRT) = 108.9 min; and clearance (Cl) = 13.3 mL/min.",Plasma pharmacokinetics of ranitidine HCl in foals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[l] / [kg],1.46,77848,DB00863,Ranitidine
,9430768,area under the curve (AUC),"Mean values for model-independent values were: apparent volume of distribution (Vdss) = 1.46 L/kg; area under the curve (AUC) = 167,442 ng.min/mL; area under the moment curve (AUMC) = 18,068,221 ng.min2/mL; mean residence time (MRT) = 108.9 min; and clearance (Cl) = 13.3 mL/min.",Plasma pharmacokinetics of ranitidine HCl in foals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[min·ng] / [ml],"167,442",77849,DB00863,Ranitidine
,9430768,area under the moment curve (AUMC),"Mean values for model-independent values were: apparent volume of distribution (Vdss) = 1.46 L/kg; area under the curve (AUC) = 167,442 ng.min/mL; area under the moment curve (AUMC) = 18,068,221 ng.min2/mL; mean residence time (MRT) = 108.9 min; and clearance (Cl) = 13.3 mL/min.",Plasma pharmacokinetics of ranitidine HCl in foals. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[min2·ng] / [ml],"18,068,221",77850,DB00863,Ranitidine
,9430768,mean residence time (MRT),"Mean values for model-independent values were: apparent volume of distribution (Vdss) = 1.46 L/kg; area under the curve (AUC) = 167,442 ng.min/mL; area under the moment curve (AUMC) = 18,068,221 ng.min2/mL; mean residence time (MRT) = 108.9 min; and clearance (Cl) = 13.3 mL/min.",Plasma pharmacokinetics of ranitidine HCl in foals. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),min,108.9,77851,DB00863,Ranitidine
,9430768,clearance (Cl),"Mean values for model-independent values were: apparent volume of distribution (Vdss) = 1.46 L/kg; area under the curve (AUC) = 167,442 ng.min/mL; area under the moment curve (AUMC) = 18,068,221 ng.min2/mL; mean residence time (MRT) = 108.9 min; and clearance (Cl) = 13.3 mL/min.",Plasma pharmacokinetics of ranitidine HCl in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[ml] / [min],13.3,77852,DB00863,Ranitidine
,9430768,AUC,"Mean values of the pharmacokinetic values from the p.o. study include: AUC = 126,413 ng.min/mL; AUMC = 18,039,825 ng.min2/mL; mean absorption time (MAT) = 32.0 min; observed time to maximum plasma concentration (Tmax) = 57.2 min; maximum observed plasma concentration (Cmax) = 635.7 ng/mL; and bioavailability (F) = 38%.",Plasma pharmacokinetics of ranitidine HCl in foals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[min·ng] / [ml],"126,413",77853,DB00863,Ranitidine
,9430768,AUMC,"Mean values of the pharmacokinetic values from the p.o. study include: AUC = 126,413 ng.min/mL; AUMC = 18,039,825 ng.min2/mL; mean absorption time (MAT) = 32.0 min; observed time to maximum plasma concentration (Tmax) = 57.2 min; maximum observed plasma concentration (Cmax) = 635.7 ng/mL; and bioavailability (F) = 38%.",Plasma pharmacokinetics of ranitidine HCl in foals. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[min2·ng] / [ml],"18,039,825",77854,DB00863,Ranitidine
,9430768,mean absorption time (MAT),"Mean values of the pharmacokinetic values from the p.o. study include: AUC = 126,413 ng.min/mL; AUMC = 18,039,825 ng.min2/mL; mean absorption time (MAT) = 32.0 min; observed time to maximum plasma concentration (Tmax) = 57.2 min; maximum observed plasma concentration (Cmax) = 635.7 ng/mL; and bioavailability (F) = 38%.",Plasma pharmacokinetics of ranitidine HCl in foals. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),min,32.0,77855,DB00863,Ranitidine
,9430768,observed time to maximum plasma concentration (Tmax),"Mean values of the pharmacokinetic values from the p.o. study include: AUC = 126,413 ng.min/mL; AUMC = 18,039,825 ng.min2/mL; mean absorption time (MAT) = 32.0 min; observed time to maximum plasma concentration (Tmax) = 57.2 min; maximum observed plasma concentration (Cmax) = 635.7 ng/mL; and bioavailability (F) = 38%.",Plasma pharmacokinetics of ranitidine HCl in foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),min,57.2,77856,DB00863,Ranitidine
,9430768,maximum observed plasma concentration (Cmax),"Mean values of the pharmacokinetic values from the p.o. study include: AUC = 126,413 ng.min/mL; AUMC = 18,039,825 ng.min2/mL; mean absorption time (MAT) = 32.0 min; observed time to maximum plasma concentration (Tmax) = 57.2 min; maximum observed plasma concentration (Cmax) = 635.7 ng/mL; and bioavailability (F) = 38%.",Plasma pharmacokinetics of ranitidine HCl in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),[ng] / [ml],635.7,77857,DB00863,Ranitidine
,9430768,bioavailability (F),"Mean values of the pharmacokinetic values from the p.o. study include: AUC = 126,413 ng.min/mL; AUMC = 18,039,825 ng.min2/mL; mean absorption time (MAT) = 32.0 min; observed time to maximum plasma concentration (Tmax) = 57.2 min; maximum observed plasma concentration (Cmax) = 635.7 ng/mL; and bioavailability (F) = 38%.",Plasma pharmacokinetics of ranitidine HCl in foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9430768/),%,38,77858,DB00863,Ranitidine
,11373465,clearance,"Pharmacokinetic variables included a clearance of 511.7 +/- 219.7 mL x kg(-1) x hr(-1), volume of distribution of 1.53 +/- 0.99 L/kg, and half-life of 3.01 +/- 1.35 hrs.",Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11373465/),[ml] / [hr·kg],511.7,80134,DB00863,Ranitidine
,11373465,volume of distribution,"Pharmacokinetic variables included a clearance of 511.7 +/- 219.7 mL x kg(-1) x hr(-1), volume of distribution of 1.53 +/- 0.99 L/kg, and half-life of 3.01 +/- 1.35 hrs.",Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11373465/),[l] / [kg],1.53,80135,DB00863,Ranitidine
,11373465,half-life,"Pharmacokinetic variables included a clearance of 511.7 +/- 219.7 mL x kg(-1) x hr(-1), volume of distribution of 1.53 +/- 0.99 L/kg, and half-life of 3.01 +/- 1.35 hrs.",Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11373465/),h,3.01,80136,DB00863,Ranitidine
,11373465,steady-state concentration,"Based on the pharmacokinetic variables, the dose of intravenous ranitidine required to target 373 ng/mL as the average steady-state concentration is 1.5 mg/kg administered every 8 hrs.",Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11373465/),[mg] / [kg],1.5,80137,DB00863,Ranitidine
,11373465,steady-state ranitidine concentration,"During the continuous infusion, the mean steady-state ranitidine concentration associated with gastric pH > or =4 was 287 +/- 133 ng/mL.",Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11373465/),[ng] / [ml],287,80138,DB00863,Ranitidine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00863,Ranitidine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00863,Ranitidine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00863,Ranitidine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00863,Ranitidine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00863,Ranitidine
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],64,80890,DB00863,Ranitidine
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],56,80891,DB00863,Ranitidine
,4064467,peak serum ibuprofen concentration,"Compared with the control state, cimetidine increased the peak serum ibuprofen concentration (64 vs. 56 micrograms/ml), but the value during ranitidine dosing (57 micrograms/ml) was indistinguishable from the control value.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[μg] / [ml],57,80892,DB00863,Ranitidine
,4064467,elimination t1/2,"There were no significant differences between control, cimetidine, and ranitidine conditions in ibuprofen elimination t1/2 (2.1, 2.1, and 2.0 hours, respectively).",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),h,2.1,80893,DB00863,Ranitidine
,4064467,elimination t1/2,"There were no significant differences between control, cimetidine, and ranitidine conditions in ibuprofen elimination t1/2 (2.1, 2.1, and 2.0 hours, respectively).",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),h,2.0,80894,DB00863,Ranitidine
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],52.8,80895,DB00863,Ranitidine
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],48.3,80896,DB00863,Ranitidine
,4064467,oral clearance,"Overall there was a significant difference among the control, cimetidine, and ranitidine conditions in ibuprofen oral clearance (52.8, 48.3, and 54.1 ml/min, respectively), but individual differences in cimetidine vs. control and between ranitidine vs. control were not statistically significant.",Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064467/),[ml] / [min],54.1,80897,DB00863,Ranitidine
,12403075,absolute bioavailability,The absolute bioavailability of ranitidine from the pellet formulation was significantly reduced by 31% (from 51% to 35%) and small intestinal liquid transit time was significantly shortened by 37% (from 226 min to 143 min) as a consequence of PEG 400 in the test preparation.,Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403075/),%,51,81966,DB00863,Ranitidine
,12403075,absolute bioavailability,The absolute bioavailability of ranitidine from the pellet formulation was significantly reduced by 31% (from 51% to 35%) and small intestinal liquid transit time was significantly shortened by 37% (from 226 min to 143 min) as a consequence of PEG 400 in the test preparation.,Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403075/),%,35,81967,DB00863,Ranitidine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,22.7,82118,DB00863,Ranitidine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,13.0,82119,DB00863,Ranitidine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,10.8,82120,DB00863,Ranitidine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],2.633,82121,DB00863,Ranitidine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],0.966,82122,DB00863,Ranitidine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[h·μg] / [ml],1.14,82123,DB00863,Ranitidine
,8838439,Km,Using the technique of simultaneous fitting across all doses the Km and Vmax constants were similar and close to literature value of 100 mg l-1 and 200-300 mg h l-1 respectively.,"Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg-1). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838439/),[mg] / [l],100,84400,DB00863,Ranitidine
,8838439,Vmax,Using the technique of simultaneous fitting across all doses the Km and Vmax constants were similar and close to literature value of 100 mg l-1 and 200-300 mg h l-1 respectively.,"Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg-1). ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838439/),[mg] / [l],100,84401,DB00863,Ranitidine
,11348484,elimination half-life,Pharmacokinetics parameters after ranitidine administration to six llamas showed a mean elimination half-life of 1.53 +/- 0.26 h.,Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,1.53,84527,DB00863,Ranitidine
,11348484,volume of distribution (Vdss),"The mean volume of distribution (Vdss) in llamas was 1.77 +/- 0.31 L/kg, and mean body clearance in llamas was 0.778 +/- 0.109 L/kg/h.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),[l] / [kg],1.77,84528,DB00863,Ranitidine
,11348484,body clearance,"The mean volume of distribution (Vdss) in llamas was 1.77 +/- 0.31 L/kg, and mean body clearance in llamas was 0.778 +/- 0.109 L/kg/h.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),[l] / [h·kg],0.778,84529,DB00863,Ranitidine
,11348484,half-life,"The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,0.61,84530,DB00863,Ranitidine
,11348484,half-life,"The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,0.72,84531,DB00863,Ranitidine
,11348484,half-life,"The mean half-life of 0.2 mg/kg i.v. omeprazole was shorter than that of 0.4 and 0.8 mg/kg i.v. omeprazole, i.e. 0.61, 0.72 and 1.07 h, respectively.",Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11348484/),h,1.07,84532,DB00863,Ranitidine
,6117305,distribution half-life (T 1/2 alpha),"The distribution half-life (T 1/2 alpha) was 6.1 +/- 0.9 min, elimination half-life (T 1/2 beta) was 1.9 +/- 0.1 h, the volume of distribution (Vd beta) was 115 +/- 7 l and systemic plasma clearance (Cltp) was 709 +/- 62 ml/min.",Pharmacokinetics of the H2- receptor antagonist ranitidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117305/),min,6.1,85183,DB00863,Ranitidine
,6117305,elimination half-life (T 1/2 beta),"The distribution half-life (T 1/2 alpha) was 6.1 +/- 0.9 min, elimination half-life (T 1/2 beta) was 1.9 +/- 0.1 h, the volume of distribution (Vd beta) was 115 +/- 7 l and systemic plasma clearance (Cltp) was 709 +/- 62 ml/min.",Pharmacokinetics of the H2- receptor antagonist ranitidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117305/),h,1.9,85184,DB00863,Ranitidine
,6117305,volume of distribution (Vd beta),"The distribution half-life (T 1/2 alpha) was 6.1 +/- 0.9 min, elimination half-life (T 1/2 beta) was 1.9 +/- 0.1 h, the volume of distribution (Vd beta) was 115 +/- 7 l and systemic plasma clearance (Cltp) was 709 +/- 62 ml/min.",Pharmacokinetics of the H2- receptor antagonist ranitidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117305/),l,115,85185,DB00863,Ranitidine
,6117305,systemic plasma clearance (Cltp),"The distribution half-life (T 1/2 alpha) was 6.1 +/- 0.9 min, elimination half-life (T 1/2 beta) was 1.9 +/- 0.1 h, the volume of distribution (Vd beta) was 115 +/- 7 l and systemic plasma clearance (Cltp) was 709 +/- 62 ml/min.",Pharmacokinetics of the H2- receptor antagonist ranitidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117305/),[ml] / [min],709,85186,DB00863,Ranitidine
,6117305,systemic availability,"3 Following 20 mg oral doses, peak levels were reached at 1.6 +/- 0.2 h and the systemic availability was 88 +/- 10%.",Pharmacokinetics of the H2- receptor antagonist ranitidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117305/),%,88,85187,DB00863,Ranitidine
,4020560,Half-life,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),h,1.8,90650,DB00863,Ranitidine
,4020560,volume of distribution,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),h,2.0,90651,DB00863,Ranitidine
,4020560,volume of distribution,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),[l] / [kg],2.3,90652,DB00863,Ranitidine
,4020560,volume of distribution,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),[l] / [kg],2.5,90653,DB00863,Ranitidine
,4020560,volume of distribution,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),[ml] / [1.73·m2·min],794.7,90654,DB00863,Ranitidine
,4020560,volume of distribution,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),[ml] / [1.73·m2·min],788.0,90655,DB00863,Ranitidine
,4020560,clearance,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),[l] / [kg],2.5,90656,DB00863,Ranitidine
,4020560,clearance,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),[ml] / [1.73·m2·min],794.7,90657,DB00863,Ranitidine
,4020560,clearance,"Half-life, volume of distribution, and clearance values for ranitidine were the same after intravenous bolus and oral doses (1.8 vs 2.0 hours, 2.3 vs 2.5 L/kg, and 794.7 vs 788.0 ml/min/1.73 m2, respectively).",Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),[ml] / [1.73·m2·min],788.0,90658,DB00863,Ranitidine
,4020560,bioavailability,The bioavailability of ranitidine given orally averaged 48%.,Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020560/),%,48,90659,DB00863,Ranitidine
,6091709,area under the plasma concentration-time curve,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[h·mg] / [l],27.761.5,91928,DB00863,Ranitidine
,6091709,area under the plasma concentration-time curve,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[h·mg] / [l],31.561.8,91929,DB00863,Ranitidine
,6091709,renal clearance,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],379632,91930,DB00863,Ranitidine
,6091709,renal clearance,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],309630,91931,DB00863,Ranitidine
,6091709,area under the plasma concentration-time curve,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),h·mg,8.661.2,91932,DB00863,Ranitidine
,6091709,area under the plasma concentration-time curve,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),h·mg,9.761.3,91933,DB00863,Ranitidine
,6091709,renal clearance,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],187630,91934,DB00863,Ranitidine
,6091709,renal clearance,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],168628,91935,DB00863,Ranitidine
,6318787,distribution volume,The mean (s.e. mean) distribution volume was 1.62 (0.08) 1/kg and the mean bioavailability 0.81 (0.05).,Ranitidine disposition in patients with renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6318787/),[1] / [kg],1.62,93248,DB00863,Ranitidine
,6318787,bioavailability,The mean (s.e. mean) distribution volume was 1.62 (0.08) 1/kg and the mean bioavailability 0.81 (0.05).,Ranitidine disposition in patients with renal impairment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6318787/),,0.81,93249,DB00863,Ranitidine
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.6,94730,DB00863,Ranitidine
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.5,94731,DB00863,Ranitidine
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94732,DB00863,Ranitidine
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94733,DB00863,Ranitidine
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94734,DB00863,Ranitidine
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94735,DB00863,Ranitidine
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,32.3,94736,DB00863,Ranitidine
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,28.9,94737,DB00863,Ranitidine
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94738,DB00863,Ranitidine
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94739,DB00863,Ranitidine
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94740,DB00863,Ranitidine
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94741,DB00863,Ranitidine
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.7,94742,DB00863,Ranitidine
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.3,94743,DB00863,Ranitidine
,6319067,Vd,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94744,DB00863,Ranitidine
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94745,DB00863,Ranitidine
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.65,94746,DB00863,Ranitidine
,18958430,yield,"The yield and drug loading amount of hollow microspheres were 83.21+/-0.28% and 20.71+/-0.32%, respectively.",In vitro and in vivo evaluation of ranitidine hydrochloride loaded hollow microspheres in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18958430/),%,83.21,95266,DB00863,Ranitidine
,18958430,drug loading amount,"The yield and drug loading amount of hollow microspheres were 83.21+/-0.28% and 20.71+/-0.32%, respectively.",In vitro and in vivo evaluation of ranitidine hydrochloride loaded hollow microspheres in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18958430/),%,20.71,95267,DB00863,Ranitidine
,17688076,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of 461.8 ng/ml (test) and 450.6 ng/ ml (reference) were achieved.,Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),[ng] / [ml],461.8,96607,DB00863,Ranitidine
,17688076,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of 461.8 ng/ml (test) and 450.6 ng/ ml (reference) were achieved.,Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),[ng] / [ml],450.6,96608,DB00863,Ranitidine
,17688076,Areas under the plasma concentration-time curve (AUC (0-infinity),"Areas under the plasma concentration-time curve (AUC (0-infinity) of 2,488.6 ng . h/ml (test) and 2,528.8 ng . h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),[h·ng] / [ml],"2,488.6",96609,DB00863,Ranitidine
,17688076,Areas under the plasma concentration-time curve (AUC (0-infinity),"Areas under the plasma concentration-time curve (AUC (0-infinity) of 2,488.6 ng . h/ml (test) and 2,528.8 ng . h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),[h·ng] / [ml],"2,528.8",96610,DB00863,Ranitidine
,17688076,tmax,The median tmax was 2.83 h (test) and 3.04 h (reference).,Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),h,2.83,96611,DB00863,Ranitidine
,17688076,tmax,The median tmax was 2.83 h (test) and 3.04 h (reference).,Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),h,3.04,96612,DB00863,Ranitidine
,17688076,Plasma elimination half-lives (t1/2),Plasma elimination half-lives (t1/2) of 2.78 h (test) and 2.89 h (reference) were determined.,Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),h,2.78,96613,DB00863,Ranitidine
,17688076,Plasma elimination half-lives (t1/2),Plasma elimination half-lives (t1/2) of 2.78 h (test) and 2.89 h (reference) were determined.,Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17688076/),h,2.89,96614,DB00863,Ranitidine
,8893041,Clp,"2. After intravenous administration, Clp was moderate (10.4 ml/min/kg) with Clr accounting for approximately 30% of total clearance.",Absorption and disposition of ranitidine hydrochloride in rat and dog. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893041/),[ml] / [kg·min],10.4,97225,DB00863,Ranitidine
,8893041,Vdarea,"Vdarea was 3.5 l/kg, resulting in a t1/2 of approximately 4 h.",Absorption and disposition of ranitidine hydrochloride in rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893041/),[l] / [kg],3.5,97226,DB00863,Ranitidine
,8893041,t1/2,"Vdarea was 3.5 l/kg, resulting in a t1/2 of approximately 4 h.",Absorption and disposition of ranitidine hydrochloride in rat and dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893041/),h,4,97227,DB00863,Ranitidine
,8893041,peak plasma concentrations,"3. After oral administration, F was good (73%) with peak plasma concentrations of ranitidine (2 micrograms/ml) achieved within 0.5-1 h hour after dosing.",Absorption and disposition of ranitidine hydrochloride in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893041/),[μg] / [ml],2,97228,DB00863,Ranitidine
,8893041,t1/2,t1/2 (4.1 h) was similar to that observed after intravenous administration.,Absorption and disposition of ranitidine hydrochloride in rat and dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893041/),h,4.1,97229,DB00863,Ranitidine
,2673663,Systemic,"Systemic and renal clearance values for cefetamet were 140 and 130 ml/min, respectively.",Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2673663/),[ml] / [min],140,101723,DB00863,Ranitidine
,2673663,renal clearance,"Systemic and renal clearance values for cefetamet were 140 and 130 ml/min, respectively.",Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2673663/),[ml] / [min],130,101724,DB00863,Ranitidine
,2673663,plasma protein binding,"The plasma protein binding is 22%, whereby the only binding protein is albumin.",Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2673663/),%,22,101725,DB00863,Ranitidine
,2673663,steady state volume of distribution,The steady state volume of distribution (0.29 l/kg) corresponds roughly to the extracellular water space which is consistent with other low protein-bound cephalosporins.,Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2673663/),[l] / [kg],0.29,101726,DB00863,Ranitidine
,2673663,F,"After oral administration, cefetamet pivoxil shows a significant food effect (F = 41% vs 51%).",Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2673663/),%,41,101727,DB00863,Ranitidine
,2673663,F,"After oral administration, cefetamet pivoxil shows a significant food effect (F = 41% vs 51%).",Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2673663/),%,51,101728,DB00863,Ranitidine
,8612382,area under the curve (AUC),"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),[h·μM] / [l],20.8,108097,DB00863,Ranitidine
,8612382,area under the curve (AUC),"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),[h·μM] / [l],23.4,108098,DB00863,Ranitidine
,8612382,peak,"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),,5,108099,DB00863,Ranitidine
,8612382,peak,"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),,6,108100,DB00863,Ranitidine
,1972124,half-life,"Beyond the peak, decrease in roxatidine concentrations was slow, as expected from a known 6-h half-life.",[Plasma pharmacokinetics of roxatidine in the healthy man: correlation with gastric antisecretory effect]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1972124/),h,6,109468,DB00863,Ranitidine
,2785905,T1/2,"For 8 patients, the mean values for T1/2, apparent volume of distribution, and total body clearance were 2.09 h, 1.61 l/kg, and 13.93 ml/min/kg, respectively.",Pharmacokinetics of ranitidine in critically ill infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785905/),h,2.09,111669,DB00863,Ranitidine
,2785905,apparent volume of distribution,"For 8 patients, the mean values for T1/2, apparent volume of distribution, and total body clearance were 2.09 h, 1.61 l/kg, and 13.93 ml/min/kg, respectively.",Pharmacokinetics of ranitidine in critically ill infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785905/),[l] / [kg],1.61,111670,DB00863,Ranitidine
,2785905,total body clearance,"For 8 patients, the mean values for T1/2, apparent volume of distribution, and total body clearance were 2.09 h, 1.61 l/kg, and 13.93 ml/min/kg, respectively.",Pharmacokinetics of ranitidine in critically ill infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785905/),[ml] / [kg·min],13.93,111671,DB00863,Ranitidine
,2735786,Elimination half-life,Elimination half-life was prolonged (3.05 +/- 0.58 h) and total clearance was reduced (282 +/- 97 ml/min) as compared to the results of studies on normal younger persons by other investigators.,Pharmacokinetics of ranitidine in geriatric patients with multiple diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735786/),h,3.05,113283,DB00863,Ranitidine
,2735786,total clearance,Elimination half-life was prolonged (3.05 +/- 0.58 h) and total clearance was reduced (282 +/- 97 ml/min) as compared to the results of studies on normal younger persons by other investigators.,Pharmacokinetics of ranitidine in geriatric patients with multiple diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735786/),[ml] / [min],282,113284,DB00863,Ranitidine
up to,8039538,AUC infinity mean ratio,"In patients with GFR < or = 20 ml min-1, the AUC infinity mean ratio (compared with normal subjects) was up to 4.6 while for patients with GFR 20-50 ml min-1, the average AUC infinity ratio was 2.6.",The effect of renal function on the pharmacokinetics of ranitidine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039538/),,4.6,113399,DB00863,Ranitidine
,8039538,AUC infinity ratio,"In patients with GFR < or = 20 ml min-1, the AUC infinity mean ratio (compared with normal subjects) was up to 4.6 while for patients with GFR 20-50 ml min-1, the average AUC infinity ratio was 2.6.",The effect of renal function on the pharmacokinetics of ranitidine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039538/),,2.6,113400,DB00863,Ranitidine
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00863,Ranitidine
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00863,Ranitidine
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00863,Ranitidine
,9570004,Plasma clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],198,117110,DB00863,Ranitidine
,9570004,Plasma clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],119,117111,DB00863,Ranitidine
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],104,117112,DB00863,Ranitidine
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],54,117113,DB00863,Ranitidine
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],89,117114,DB00863,Ranitidine
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],18.4,117115,DB00863,Ranitidine
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],13.6,117116,DB00863,Ranitidine
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],3.9,117117,DB00863,Ranitidine
,9570004,inhibition constants,"Estimated inhibition constants of cimetidine and probenecid were 62 and 4 micrograms mL-1, respectively.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[μg] / [ml],62,117118,DB00863,Ranitidine
,9570004,inhibition constants,"Estimated inhibition constants of cimetidine and probenecid were 62 and 4 micrograms mL-1, respectively.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[μg] / [ml],4,117119,DB00863,Ranitidine
,2658392,lesions score,In the corresponding acemetacin-series the lesions score was 1.6 +/- 0.1 (+/- SEM).,"[Ranitidine ameliorates acemetacin and indomethacin-induced changes of the gastroduodenal mucosa, without modifying the pharmacokinetic behavior of both antirheumatic drugs]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658392/),,1.6,118178,DB00863,Ranitidine
,2710266,peak serum ranitidine concentration,"Following i.v. administration, the peak serum ranitidine concentration was 761 +/- 207 micrograms/l (mean +/- SD) and the observed peak after the oral dose was 833 +/- 206 micrograms/l at 3.5 +/- 1.2 h.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),[μg] / [l],761,121182,DB00863,Ranitidine
,2710266,observed peak after,"Following i.v. administration, the peak serum ranitidine concentration was 761 +/- 207 micrograms/l (mean +/- SD) and the observed peak after the oral dose was 833 +/- 206 micrograms/l at 3.5 +/- 1.2 h.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),[μg] / [l],833,121183,DB00863,Ranitidine
,2710266,terminal elimination rate constants,"The terminal elimination rate constants for the i.v. and oral doses were 0.062 +/- 0.013 and 0.058 +/- 0.004 h-1, respectively, with an apparent volume of distribution of 139.6 +/- 35.3 liters and total body clearance 8.5 +/- 1.6 liters/h for the i.v. dose.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),1/[h],0.062,121184,DB00863,Ranitidine
,2710266,terminal elimination rate constants,"The terminal elimination rate constants for the i.v. and oral doses were 0.062 +/- 0.013 and 0.058 +/- 0.004 h-1, respectively, with an apparent volume of distribution of 139.6 +/- 35.3 liters and total body clearance 8.5 +/- 1.6 liters/h for the i.v. dose.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),1/[h],0.058,121185,DB00863,Ranitidine
,2710266,apparent volume of distribution,"The terminal elimination rate constants for the i.v. and oral doses were 0.062 +/- 0.013 and 0.058 +/- 0.004 h-1, respectively, with an apparent volume of distribution of 139.6 +/- 35.3 liters and total body clearance 8.5 +/- 1.6 liters/h for the i.v. dose.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),l,139.6,121186,DB00863,Ranitidine
,2710266,total body clearance,"The terminal elimination rate constants for the i.v. and oral doses were 0.062 +/- 0.013 and 0.058 +/- 0.004 h-1, respectively, with an apparent volume of distribution of 139.6 +/- 35.3 liters and total body clearance 8.5 +/- 1.6 liters/h for the i.v. dose.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),[l] / [h],8.5,121187,DB00863,Ranitidine
,2710266,clearances,"Hemodialysis clearances during the i.v. and oral studies were 3.2 +/- 0.9 and 3.1 +/- 1.0 liters/h, respectively, and the mean amount removed by hemodialysis following i.v. administration was 3.9 +/- 2.7 mg.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),[l] / [h],3.2,121188,DB00863,Ranitidine
,2710266,clearances,"Hemodialysis clearances during the i.v. and oral studies were 3.2 +/- 0.9 and 3.1 +/- 1.0 liters/h, respectively, and the mean amount removed by hemodialysis following i.v. administration was 3.9 +/- 2.7 mg.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),[l] / [h],3.1,121189,DB00863,Ranitidine
,2710266,amount removed,"Hemodialysis clearances during the i.v. and oral studies were 3.2 +/- 0.9 and 3.1 +/- 1.0 liters/h, respectively, and the mean amount removed by hemodialysis following i.v. administration was 3.9 +/- 2.7 mg.",Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),mg,3.9,121190,DB00863,Ranitidine
,2710266,bioavailability,The bioavailability of ranitidine was 54.3 +/- 13.5%.,Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2710266/),%,54.3,121191,DB00863,Ranitidine
,8877680,terminal half-life,"The terminal half-life of ranitidine was 7% shorter and the oral apparent clearance 10.5% higher in women (1.44 L/h/kg) than in men (1.29 L/h/kg), although this difference did not reach statistical significance.",Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877680/),[l] / [h·kg],1.44,121405,DB00863,Ranitidine
,8877680,oral apparent clearance,"The terminal half-life of ranitidine was 7% shorter and the oral apparent clearance 10.5% higher in women (1.44 L/h/kg) than in men (1.29 L/h/kg), although this difference did not reach statistical significance.",Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877680/),[l] / [h·kg],1.29,121406,DB00863,Ranitidine
,8364260,Peak ethanol concentrations,"Peak ethanol concentrations (median values) were 153, 140, and 155 mg/L, respectively.",Comparative trial in volunteers to investigate possible ethanol-ranitidine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364260/),[mg] / [l],153,122115,DB00863,Ranitidine
,8364260,Peak ethanol concentrations,"Peak ethanol concentrations (median values) were 153, 140, and 155 mg/L, respectively.",Comparative trial in volunteers to investigate possible ethanol-ranitidine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364260/),[mg] / [l],140,122116,DB00863,Ranitidine
,8364260,Peak ethanol concentrations,"Peak ethanol concentrations (median values) were 153, 140, and 155 mg/L, respectively.",Comparative trial in volunteers to investigate possible ethanol-ranitidine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364260/),[mg] / [l],155,122117,DB00863,Ranitidine
,6313378,t1/2,"The terminal elimination rate constant (beta) was significantly smaller (p less than 0.001) in CRF group when compared with N group resulting in a median t1/2 for the CRF group of 7.3 h, 2.4 times that of N group.",Pharmacokinetics of ranitidine in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313378/),h,7.3,124468,DB00863,Ranitidine
,8314361,t1/2 beta,The mean t1/2 beta of naproxen in 6 subjects was 25.7 +/- 5.4 h (range 16 to 36).,"The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25.7,124746,DB00863,Ranitidine
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25,124747,DB00863,Ranitidine
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,13,124748,DB00863,Ranitidine
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,4.0,124749,DB00863,Ranitidine
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,1.1,124750,DB00863,Ranitidine
,4059323,elimination half-life,"The elimination half-life, plasma clearance and volume of distribution (VD area) of ranitidine in these patients were 9.0 +/- 2.6 h (mean +/- SD), 305 +/- 152 ml/min and 3.5 +/- 1.9 liters/kg, respectively.",Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4059323/),h,9.0,125727,DB00863,Ranitidine
,4059323,plasma clearance,"The elimination half-life, plasma clearance and volume of distribution (VD area) of ranitidine in these patients were 9.0 +/- 2.6 h (mean +/- SD), 305 +/- 152 ml/min and 3.5 +/- 1.9 liters/kg, respectively.",Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4059323/),[ml] / [min],305,125728,DB00863,Ranitidine
,4059323,volume of distribution (VD area),"The elimination half-life, plasma clearance and volume of distribution (VD area) of ranitidine in these patients were 9.0 +/- 2.6 h (mean +/- SD), 305 +/- 152 ml/min and 3.5 +/- 1.9 liters/kg, respectively.",Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4059323/),[l] / [kg],3.5,125729,DB00863,Ranitidine
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB00863,Ranitidine
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB00863,Ranitidine
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB00863,Ranitidine
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB00863,Ranitidine
,24258773,Ratio of AUC pH to AUC drug concentration 0-12 hours,Ratio of AUC pH to AUC drug concentration 0-12 hours after first dose was significantly greater for famotidine (0.06849 ± 0.01460 SD) than ranitidine (0.02453 ± 0.01448; p < 0.001) demonstrating greater potency of famotidine.,Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258773/),,0.06849,133286,DB00863,Ranitidine
,24258773,Ratio of AUC pH to AUC drug concentration 0-12 hours,Ratio of AUC pH to AUC drug concentration 0-12 hours after first dose was significantly greater for famotidine (0.06849 ± 0.01460 SD) than ranitidine (0.02453 ± 0.01448; p < 0.001) demonstrating greater potency of famotidine.,Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258773/),,0.02453,133287,DB00863,Ranitidine
,27858108,absolute oral bioavailability,The absolute oral bioavailability of fostamatinib was 54.6 %.,"Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27858108/),%,54.6,135217,DB00863,Ranitidine
,27858108,absolute oral bioavailability,The absolute oral bioavailability of fostamatinib was ~55 %.,"Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27858108/),%,55,135218,DB00863,Ranitidine
,6094785,bioavailability,"By using intravenous administration as a reference dosage form and the integrated form of the regression equations to calculate the AUC values, the bioavailability of the oral dose was found to be 0.56, which corresponds well with the value of 0.58 obtained by linear-log-linear integration.",Pharmacokinetics and bioavailability of ranitidine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6094785/),,0.56,135860,DB00863,Ranitidine
,6094785,bioavailability,"By using intravenous administration as a reference dosage form and the integrated form of the regression equations to calculate the AUC values, the bioavailability of the oral dose was found to be 0.56, which corresponds well with the value of 0.58 obtained by linear-log-linear integration.",Pharmacokinetics and bioavailability of ranitidine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6094785/),,0.58,135861,DB00863,Ranitidine
,16098001,eradication rates,"On an intention-to-treat basis, eradication rates were 91 and 76% for the RCM and OCM groups respectively (P < 0.02).","Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16098001/),%,91,136422,DB00863,Ranitidine
,16098001,eradication rates,"On an intention-to-treat basis, eradication rates were 91 and 76% for the RCM and OCM groups respectively (P < 0.02).","Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16098001/),%,76,136423,DB00863,Ranitidine
,9816021,maximum tolerated dose,The maximum tolerated dose of paclitaxel by a 3-h infusion was determined to be 240 mg/m2.,Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816021/),[mg] / [m],240,136639,DB00863,Ranitidine
,3443254,plasma ICG clearance,"In 31 patients treated with ranitidine (150 mg perorally), the plasma ICG clearance were 233.6 +/- 20.4 ml/min (mean +/- S.E.) and 239.2 +/- 20.5 ml/min before and after ranitidine, respectively.",Effects of ranitidine on plasma clearance of indocyanine green in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443254/),[ml] / [min],233.6,136653,DB00863,Ranitidine
,3443254,plasma ICG clearance,"In 31 patients treated with ranitidine (150 mg perorally), the plasma ICG clearance were 233.6 +/- 20.4 ml/min (mean +/- S.E.) and 239.2 +/- 20.5 ml/min before and after ranitidine, respectively.",Effects of ranitidine on plasma clearance of indocyanine green in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443254/),[ml] / [min],239.2,136654,DB00863,Ranitidine
,2275223,volume of distribution,Ranitidine volume of distribution and clearance were significantly smaller in the obese subjects per kilogram of total body weight (1.45 vs. 0.80 L/kg and 0.59 vs.,Pharmacokinetics of ranitidine in morbidly obese women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2275223/),[l] / [kg],1.45,138227,DB00863,Ranitidine
,2275223,clearance,Ranitidine volume of distribution and clearance were significantly smaller in the obese subjects per kilogram of total body weight (1.45 vs. 0.80 L/kg and 0.59 vs.,Pharmacokinetics of ranitidine in morbidly obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2275223/),,0.59,138228,DB00863,Ranitidine
,8070508,maximum blood concentration,The mean maximum blood concentration of CsA for the oral dose was 776 ng.,Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),ng,776,141552,DB00863,Ranitidine
,8070508,peak values,"ml-1 for the 7 CF subjects, which was comparable with the mean peak values of 789 ng.",Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),ng,789,141553,DB00863,Ranitidine
,8070508,bioavailability,Poor enteral absorption of CsA probably accounts for the significantly lower mean bioavailability in the 7 CF subjects (14.9%) compared with the 3 non-CF control subjects (39.4%).,Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),%,14.9,141554,DB00863,Ranitidine
,8070508,bioavailability,Poor enteral absorption of CsA probably accounts for the significantly lower mean bioavailability in the 7 CF subjects (14.9%) compared with the 3 non-CF control subjects (39.4%).,Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),%,39.4,141555,DB00863,Ranitidine
,1342209,area under the curve for 24-h (AUC0-24),"3. Ranitidine coadministration increased the area under the curve for 24-h (AUC0-24) plasma concentration vs time, from 49.07 +/- 6.28 micrograms.h/l to 82.35 +/- 2.57 micrograms.h/l (P < 0.01).",Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[h·μg] / [l],49.07,142366,DB00863,Ranitidine
,1342209,area under the curve for 24-h (AUC0-24),"3. Ranitidine coadministration increased the area under the curve for 24-h (AUC0-24) plasma concentration vs time, from 49.07 +/- 6.28 micrograms.h/l to 82.35 +/- 2.57 micrograms.h/l (P < 0.01).",Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[h·μg] / [l],82.35,142367,DB00863,Ranitidine
,1342209,total body clearance,This significant increase caused a reduction in total body clearance from 2008.33 +/- 246.33 to 1284.00 +/- 182.16 ml/min (P < 0.002).,Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[ml] / [min],2008.33,142368,DB00863,Ranitidine
,1342209,total body clearance,This significant increase caused a reduction in total body clearance from 2008.33 +/- 246.33 to 1284.00 +/- 182.16 ml/min (P < 0.002).,Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[ml] / [min],1284.00,142369,DB00863,Ranitidine
,11352441,area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],35.5,142404,DB00863,Ranitidine
,11352441,area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],34.3,142405,DB00863,Ranitidine
,11352441,relative bioavailability,"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,103,142406,DB00863,Ranitidine
,11352441,maximum plasma concentration (Cmax),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.98,142407,DB00863,Ranitidine
,11352441,maximum plasma concentration (Cmax),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.76,142408,DB00863,Ranitidine
,11352441,AUCinfinity,"When moxifloxacin was given simultaneously with Maalox 70, AUCinfinity ( 14.7 mg/L x h) and Cmax (1.00 mg/L) were reduced by approximately 60%.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],14.7,142409,DB00863,Ranitidine
,11352441,Cmax,"When moxifloxacin was given simultaneously with Maalox 70, AUCinfinity ( 14.7 mg/L x h) and Cmax (1.00 mg/L) were reduced by approximately 60%.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],1.00,142410,DB00863,Ranitidine
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],28.0,142411,DB00863,Ranitidine
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],26.7,142412,DB00863,Ranitidine
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],34.3,142413,DB00863,Ranitidine
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,9.4,142414,DB00863,Ranitidine
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,9.3,142415,DB00863,Ranitidine
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,12.3,142416,DB00863,Ranitidine
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.55,142417,DB00863,Ranitidine
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.38,142418,DB00863,Ranitidine
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.57,142419,DB00863,Ranitidine
,11352441,bioavailabilities,"The mean bioavailabilities corrected for the elimination rate constants (lambdaz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70 may interfere with the gastrointestinal recirculation of moxifloxacin.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,101,142420,DB00863,Ranitidine
,11352441,bioavailabilities,"The mean bioavailabilities corrected for the elimination rate constants (lambdaz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70 may interfere with the gastrointestinal recirculation of moxifloxacin.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,98,142421,DB00863,Ranitidine
,3615159,steady-state drug concentrations,Quite constant steady-state drug concentrations were achieved in the range of 64-123 ng/ml plasma (mean Css: 100.6 ng/ml).,Kinetics of rate controlled rectally administered ranitidine to male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3615159/),[ng] / [ml·plasma],64-123,144472,DB00863,Ranitidine
,3615159,Css,Quite constant steady-state drug concentrations were achieved in the range of 64-123 ng/ml plasma (mean Css: 100.6 ng/ml).,Kinetics of rate controlled rectally administered ranitidine to male volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3615159/),[ng] / [ml],100.6,144473,DB00863,Ranitidine
,3615159,mean absorption time,"The mean absorption time was 0.45 h (range 0-I.02 h), indicating that absorption was not always instantaneous.",Kinetics of rate controlled rectally administered ranitidine to male volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3615159/),h,0.45,144474,DB00863,Ranitidine
,8473547,maximum plasma concentration,"The maximum plasma concentration of ritanserin was decreased significantly (105.0 +/- 9.2 versus 125.0 +/- 13.8 ng/mL; P = .0039), whereas time to reach maximal concentration (tmax) of ritanserin was only slightly but not significantly increased, if the subjects were pretreated with cimetidine.",Effect of concomitantly administered cimetidine or ranitidine on the pharmacokinetics of the 5-HT2-receptor antagonist ritanserin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473547/),[ng] / [ml],105.0,145022,DB00863,Ranitidine
,8473547,maximum plasma concentration,"The maximum plasma concentration of ritanserin was decreased significantly (105.0 +/- 9.2 versus 125.0 +/- 13.8 ng/mL; P = .0039), whereas time to reach maximal concentration (tmax) of ritanserin was only slightly but not significantly increased, if the subjects were pretreated with cimetidine.",Effect of concomitantly administered cimetidine or ranitidine on the pharmacokinetics of the 5-HT2-receptor antagonist ritanserin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8473547/),[ng] / [ml],125.0,145023,DB00863,Ranitidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,6,146832,DB00863,Ranitidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,8,146833,DB00863,Ranitidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,12,146834,DB00863,Ranitidine
,19853541,total run time,The total run time was 7 min per sample.,A single LC-tandem mass spectrometry method for the simultaneous determination of four H2 antagonists in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853541/),[min] / [sample],7,146976,DB00863,Ranitidine
,6315329,plasma level peaks,"After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml.",[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6315329/),[ng] / [ml],87.7,151428,DB00863,Ranitidine
,6315329,plasma level peaks,"After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml.",[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6315329/),[ng] / [ml],46.1,151429,DB00863,Ranitidine
,28176470,tmax,Median tmax was delayed from 5 to 6 hours.,Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176470/),h,5,156993,DB00863,Ranitidine
,28176470,tmax,Median tmax was delayed from 5 to 6 hours.,Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176470/),h,6,156994,DB00863,Ranitidine
,6126422,bioavailability,In the first of these bioavailability was 51 +/- 4% and half life 161 +/- 11 minutes after oral and 124 +/- 5 minutes after intravenous administration.,Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126422/),%,51,157256,DB00863,Ranitidine
,6126422,half life,In the first of these bioavailability was 51 +/- 4% and half life 161 +/- 11 minutes after oral and 124 +/- 5 minutes after intravenous administration.,Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126422/),min,161,157257,DB00863,Ranitidine
,6126422,half life,In the first of these bioavailability was 51 +/- 4% and half life 161 +/- 11 minutes after oral and 124 +/- 5 minutes after intravenous administration.,Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126422/),min,124,157258,DB00863,Ranitidine
,6126422,bioavailability,"In the cirrhotics bioavailability was increased to 70 +/- 7%, clearance was reduced, and there was a modest increase in half life.",Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126422/),,70,157259,DB00863,Ranitidine
,6126422,half life,"In the elderly bioavailability was similar to that in young adults, clearance was markedly reduced, and half life was prolonged to 241 +/- 7 minutes after oral and 194 +/- 11 minutes after intravenous administration.",Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126422/),min,241,157260,DB00863,Ranitidine
,6126422,half life,"In the elderly bioavailability was similar to that in young adults, clearance was markedly reduced, and half life was prolonged to 241 +/- 7 minutes after oral and 194 +/- 11 minutes after intravenous administration.",Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126422/),min,194,157261,DB00863,Ranitidine
,2882981,maximum rate of secretory transport (Tm),The maximum rate of secretory transport (Tm) of famotidine averaged 180 micrograms/min/kg.,Urinary excretion kinetics of famotidine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882981/),[μg] / [kg·min],180,158928,DB00863,Ranitidine
exceeded,8864318,peak plasma concentrations,"2. Bismuth was only minimally absorbed (< 0.5% of the amount dosed) after administration of ranitidine bismuth citrate, and peak plasma concentrations never exceeded 33 ng ml-1 in any subject.",Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864318/),[ng] / [ml],33,161346,DB00863,Ranitidine
,4085354,area under the plasma concentration-time curve,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),[h·μg] / [ml],324.2,161820,DB00863,Ranitidine
,4085354,area under the plasma concentration-time curve,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),[h·μg] / [ml],326.3,161821,DB00863,Ranitidine
,4085354,elimination half-life,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),h,32.2,161822,DB00863,Ranitidine
,4085354,elimination half-life,"Ranitidine did not change the carbamazepine area under the plasma concentration-time curve (324.2 +/- 71.1 micrograms h/ml, placebo vs. 326.3 +/- 65.0 micrograms h/ml, ranitidine; p = 0.84) or the elimination half-life (32.2 +/- 6.4 h, placebo vs. 31.7 +/- 6.1 h, ranitidine; p = 0.62).",Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085354/),h,31.7,161823,DB00863,Ranitidine
,8218756,IC50,Inhibition of acid secretion was related to plasma ranitidine concentration; the mean IC50 was 27 (+/- 6.4) ng/ml.,Anti-secretory effects and pharmacokinetics of low dose ranitidine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218756/),[ng] / [ml],27,162035,DB00863,Ranitidine
,22764568,recovered amounts,The recovered amounts of quinidine 30 min after administration were 21.1% of dose in control rats and 94.7% in ranitidine-treated rats.,"Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764568/),%,21.1,162642,DB00863,Ranitidine
,22764568,recovered amounts,The recovered amounts of quinidine 30 min after administration were 21.1% of dose in control rats and 94.7% in ranitidine-treated rats.,"Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764568/),%,94.7,162643,DB00863,Ranitidine
,26538490,flow rate,"The flow rate was set at 1.0 mL min(-1), and the effluent was monitored by UV detector at 280 nm FAM and 320 nm for NIZ and RAN.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[ml] / [min],1.0,164152,DB00863,Ranitidine
,26538490,limits of detections,"The limits of detections and quantitations were 0.008-0.011 and 0.025-0.033 µg mL(-1), respectively.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[μg] / [ml],0.008-0.011,164153,DB00863,Ranitidine
,26538490,limits of detections,"The limits of detections and quantitations were 0.008-0.011 and 0.025-0.033 µg mL(-1), respectively.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[μg] / [ml],0.025-0.033,164154,DB00863,Ranitidine
,10460068,kout,"For administration of a single dose, estimated pharmacodynamic parameters were 4.5 +/- 0.9 h(-1) for kout, 1.4 +/- 0.1 for baseline pH, 0.051 +/- 0.012 mg/L for 50% inhibition constant, and 7.0 +/- 1.5 for Hill factor (mean +/- SEM; n = 18).",Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460068/),1/[h],4.5,164293,DB00863,Ranitidine
,10460068,base,"For administration of a single dose, estimated pharmacodynamic parameters were 4.5 +/- 0.9 h(-1) for kout, 1.4 +/- 0.1 for baseline pH, 0.051 +/- 0.012 mg/L for 50% inhibition constant, and 7.0 +/- 1.5 for Hill factor (mean +/- SEM; n = 18).",Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460068/),,1.4,164294,DB00863,Ranitidine
,10460068,50% inhibition constant,"For administration of a single dose, estimated pharmacodynamic parameters were 4.5 +/- 0.9 h(-1) for kout, 1.4 +/- 0.1 for baseline pH, 0.051 +/- 0.012 mg/L for 50% inhibition constant, and 7.0 +/- 1.5 for Hill factor (mean +/- SEM; n = 18).",Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460068/),[mg] / [l],0.051,164295,DB00863,Ranitidine
,10460068,Hill factor,"For administration of a single dose, estimated pharmacodynamic parameters were 4.5 +/- 0.9 h(-1) for kout, 1.4 +/- 0.1 for baseline pH, 0.051 +/- 0.012 mg/L for 50% inhibition constant, and 7.0 +/- 1.5 for Hill factor (mean +/- SEM; n = 18).",Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460068/),,7.0,164296,DB00863,Ranitidine
,10460068,beta,"Tolerance developed during subsequent dosing that could be described as a linear increase (beta) of 50% inhibition constant with time (beta = 0.0030 and 0.0045 mg/L/h for repeated and continuous administration, respectively).",Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460068/),[mg] / [h·l],0.0030,164297,DB00863,Ranitidine
,10460068,beta,"Tolerance developed during subsequent dosing that could be described as a linear increase (beta) of 50% inhibition constant with time (beta = 0.0030 and 0.0045 mg/L/h for repeated and continuous administration, respectively).",Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460068/),[mg] / [h·l],0.0045,164298,DB00863,Ranitidine
,1444308,relative bioavailability,"When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone.","Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444308/),%,56,166262,DB00863,Ranitidine
,1444308,relative bioavailability,"When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone.","Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444308/),%,81,166263,DB00863,Ranitidine
,1444308,relative bioavailability,"When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone.","Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444308/),%,78,166264,DB00863,Ranitidine
,8437966,plasma half-life,"Famotidine's plasma half-life (4.42 hrs) was significantly longer than ranitidine's (3.14 hrs, p < 0.05, paired t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,4.42,167036,DB00863,Ranitidine
,8437966,plasma half-life,"Famotidine's plasma half-life (4.42 hrs) was significantly longer than ranitidine's (3.14 hrs, p < 0.05, paired t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,3.14,167037,DB00863,Ranitidine
,8437966,duration of effect,"The duration of effect (defined as median pH > 4) was similar for ranitidine and famotidine, 10.3 and 9.9 hours, respectively (p = 0.713, paired Student's t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,10.3,167038,DB00863,Ranitidine
,8437966,duration of effect,"The duration of effect (defined as median pH > 4) was similar for ranitidine and famotidine, 10.3 and 9.9 hours, respectively (p = 0.713, paired Student's t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,9.9,167039,DB00863,Ranitidine
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],973,167821,DB00863,Ranitidine
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],710,167822,DB00863,Ranitidine
,3111514,AUC,"Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control.",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·ng] / [ml],726,167823,DB00863,Ranitidine
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],8.25,167824,DB00863,Ranitidine
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],6.0,167825,DB00863,Ranitidine
,3111514,Apparent oral glibenclamide clearance,Apparent oral glibenclamide clearance decreased from 8.25 l h-1 under the control treatment to 6.0 l h-1 following cimetidine but was unchanged during ranitidine (7.97 l h-1).,The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[l] / [h],7.97,167826,DB00863,Ranitidine
,3111514,glucose,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],237,167827,DB00863,Ranitidine
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],237,167828,DB00863,Ranitidine
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],228,167829,DB00863,Ranitidine
,3111514,AUC,"Plasma glucose concentrations were unexpectedly higher when glibenclamide was administered with cimetidine or ranitidine (glucose AUC 237 mg dl-1 h, 228 mg dl-1 h) when compared with glibenclamide administered alone (195 mg dl-1 h, P less than 0.0001).",The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3111514/),[h·mg] / [dl],195,167830,DB00863,Ranitidine
,16718762,C(max),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[mg] / [l],0.67,167913,DB00863,Ranitidine
,16718762,C(max),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[mg] / [l],0.68,167914,DB00863,Ranitidine
,16718762,AUC( (0-t) ),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[mg] / [h·l],3.1,167915,DB00863,Ranitidine
,16718762,AUC( (0-t) ),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[mg] / [h·l],3.0,167916,DB00863,Ranitidine
,16718762,AUC( (0-infinity) ),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[mg] / [h·l],3.3,167917,DB00863,Ranitidine
,16718762,AUC( (0-infinity) ),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[mg] / [h·l],3.2,167918,DB00863,Ranitidine
,16718762,T(max),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),h,2.3,167919,DB00863,Ranitidine
,16718762,T(max),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),h,2.1,167920,DB00863,Ranitidine
,16718762,T((1/2)),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),h,2.8,167921,DB00863,Ranitidine
,16718762,T((1/2)),"These parameters derived from test and reference drug were as follows: C(max) (0.67 +/- 0.21 vs 0.68 +/-0.22 mg/L), AUC( (0-t) ) (3.1 +/- 0.6 vs 3.0 +/- 0.7 mg/L per hour), AUC( (0-infinity) ) (3.3 +/- 0.6 vs 3.2 +/- 0.8 mg/L per hour), T(max) (2.3 +/- 0.9 vs 2.1 +/- 0.9 h) and T((1/2)) (2.8 +/- 0.3 vs 3.1 +/- 0.4 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),h,3.1,167922,DB00863,Ranitidine
,16718762,C(max),"For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[μg] / [l],11.80,167923,DB00863,Ranitidine
,16718762,C(max),"For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[μg] / [l],11.40,167924,DB00863,Ranitidine
,16718762,AUC( (0-t) ),"For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[μg] / [h·l],46.65,167925,DB00863,Ranitidine
,16718762,AUC( (0-t) ),"For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),[μg] / [h·l],47.03,167926,DB00863,Ranitidine
,16718762,T(max),"For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),h,0.50,167927,DB00863,Ranitidine
,16718762,T((1/2)),"For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),h,10.2,167928,DB00863,Ranitidine
,16718762,T((1/2)),"For bismuth, those parameters derived from test and reference drug were as follows: C(max) (11.80 +/- 7.36 vs 11.40 +/- 6.55 microg/L), AUC( (0-t) ) (46.65 +/- 16.97 vs 47.03 +/- 21.49 microg/L per hour), T(max) (0.50 +/- 0.20 vs 0.50 +/- 0.20 h) and T((1/2)) (10.2 +/- 2.3 vs 13.0 +/- 6.9 h).",Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16718762/),h,13.0,167929,DB00863,Ranitidine
,15470533,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 44 ng/ml (metoclopramide alone) and 49.2 ng/ml (metoclopramide and ranitidine).",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[ng] / [ml],44,168884,DB00863,Ranitidine
,15470533,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 44 ng/ml (metoclopramide alone) and 49.2 ng/ml (metoclopramide and ranitidine).",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[ng] / [ml],49.2,168885,DB00863,Ranitidine
,15470533,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.15 hrs, and 1.21 hrs, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,1.15,168886,DB00863,Ranitidine
,15470533,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.15 hrs, and 1.21 hrs, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,1.21,168887,DB00863,Ranitidine
,15470533,total areas under the curve (AUC),"The total areas under the curve (AUC) was 314.3 ng.hr/ml and 354.06 ng.hr/ml, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[h·ng] / [ml],314.3,168888,DB00863,Ranitidine
,15470533,total areas under the curve (AUC),"The total areas under the curve (AUC) was 314.3 ng.hr/ml and 354.06 ng.hr/ml, respectively.",Pharmacokinetic interaction study between ranitidine and metoclopramide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),[h·ng] / [ml],354.06,168889,DB00863,Ranitidine
,15470533,half-life (T 1/2),The half-life (T 1/2) was 5.6 hr and 6.7 hr.,Pharmacokinetic interaction study between ranitidine and metoclopramide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,5.6,168890,DB00863,Ranitidine
,15470533,half-life (T 1/2),The half-life (T 1/2) was 5.6 hr and 6.7 hr.,Pharmacokinetic interaction study between ranitidine and metoclopramide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470533/),h,6.7,168891,DB00863,Ranitidine
,16638738,time to maximum concentration (t(max)),"In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,1.25,170198,DB00863,Ranitidine
,16638738,Time to maximum PT,"Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,0.5,170199,DB00863,Ranitidine
,16638738,Time to maximum PT,"Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,1.5,170200,DB00863,Ranitidine
,18600434,cumulative amount,"In the male volunteers, the mean cumulative amount of ranitidine excreted in the presence of 0, 0.5, 0.75, 1, 1.25 and 1.5 g PEG 400 were 35, 47, 57, 52, 50 and 37 mg respectively.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),mg,35,171749,DB00863,Ranitidine
,18600434,cumulative amount,"In the male volunteers, the mean cumulative amount of ranitidine excreted in the presence of 0, 0.5, 0.75, 1, 1.25 and 1.5 g PEG 400 were 35, 47, 57, 52, 50 and 37 mg respectively.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),mg,47,171750,DB00863,Ranitidine
,18600434,cumulative amount,"In the male volunteers, the mean cumulative amount of ranitidine excreted in the presence of 0, 0.5, 0.75, 1, 1.25 and 1.5 g PEG 400 were 35, 47, 57, 52, 50 and 37 mg respectively.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),mg,57,171751,DB00863,Ranitidine
,18600434,cumulative amount,"In the male volunteers, the mean cumulative amount of ranitidine excreted in the presence of 0, 0.5, 0.75, 1, 1.25 and 1.5 g PEG 400 were 35, 47, 57, 52, 50 and 37 mg respectively.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),mg,52,171752,DB00863,Ranitidine
,18600434,cumulative amount,"In the male volunteers, the mean cumulative amount of ranitidine excreted in the presence of 0, 0.5, 0.75, 1, 1.25 and 1.5 g PEG 400 were 35, 47, 57, 52, 50 and 37 mg respectively.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),mg,50,171753,DB00863,Ranitidine
,18600434,cumulative amount,"In the male volunteers, the mean cumulative amount of ranitidine excreted in the presence of 0, 0.5, 0.75, 1, 1.25 and 1.5 g PEG 400 were 35, 47, 57, 52, 50 and 37 mg respectively.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),mg,37,171754,DB00863,Ranitidine
,18600434,bioavailability,"These correspond to increases in bioavailability of 34%, 63%, 49%, 43% and 6% over the control treatment.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),%,63,171755,DB00863,Ranitidine
,18600434,bioavailability,"These correspond to increases in bioavailability of 34%, 63%, 49%, 43% and 6% over the control treatment.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),%,49,171756,DB00863,Ranitidine
,18600434,bioavailability,"These correspond to increases in bioavailability of 34%, 63%, 49%, 43% and 6% over the control treatment.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),%,43,171757,DB00863,Ranitidine
,18600434,bioavailability,"These correspond to increases in bioavailability of 34%, 63%, 49%, 43% and 6% over the control treatment.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),%,6,171758,DB00863,Ranitidine
,18600434,bioavailability,"In the female subjects, the mean cumulative quantity of ranitidine excretion in the absence and presence of increasing amounts of PEG 400 were 38, 29, 35, 33, 33 and 33 mg, corresponding to decreases in bioavailability of 24%, 8%, 13%, 13% and 13% compared to the control.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),%,24,171759,DB00863,Ranitidine
,18600434,bioavailability,"In the female subjects, the mean cumulative quantity of ranitidine excretion in the absence and presence of increasing amounts of PEG 400 were 38, 29, 35, 33, 33 and 33 mg, corresponding to decreases in bioavailability of 24%, 8%, 13%, 13% and 13% compared to the control.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),%,8,171760,DB00863,Ranitidine
,18600434,bioavailability,"In the female subjects, the mean cumulative quantity of ranitidine excretion in the absence and presence of increasing amounts of PEG 400 were 38, 29, 35, 33, 33 and 33 mg, corresponding to decreases in bioavailability of 24%, 8%, 13%, 13% and 13% compared to the control.",Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18600434/),%,13,171761,DB00863,Ranitidine
,1764869,distribution half-life,"After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and an elimination half-life of about 2 to 4h.",Clinical pharmacokinetics of famotidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),h,0.18 to 0.5,172321,DB00863,Ranitidine
,1764869,elimination half-life,"After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and an elimination half-life of about 2 to 4h.",Clinical pharmacokinetics of famotidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),h,2 to 4,172322,DB00863,Ranitidine
,1764869,volume of distribution of the drug at steady-state,The volume of distribution of the drug at steady-state ranges from 1.0 to 1.3 L/kg; plasma protein binding is low (15 to 22%).,Clinical pharmacokinetics of famotidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),[l] / [kg],1.0 to 1.3,172323,DB00863,Ranitidine
,1764869,plasma protein binding,The volume of distribution of the drug at steady-state ranges from 1.0 to 1.3 L/kg; plasma protein binding is low (15 to 22%).,Clinical pharmacokinetics of famotidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),%,15 to 22,172324,DB00863,Ranitidine
,1764869,renal clearance,"Because its renal clearance (15 L/h) far exceeds the glomerular filtration rate, famotidine is considered to be eliminated not only via glomerular filtration but also via renal tubular secretion.",Clinical pharmacokinetics of famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),[l] / [h],15,172325,DB00863,Ranitidine
,1764869,oral bioavailability,"After oral administration, peak plasma concentrations are attained within 2 to 4h; the oral bioavailability ranges from 40 to 50%, due mainly to incomplete absorption.",Clinical pharmacokinetics of famotidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),%,40 to 50,172326,DB00863,Ranitidine
,11863299,RF,The RF value obtained for the drug was 0.67 +/- 0.03.,Development of a sensitive high-performance thin-layer chromatography method for estimation of ranitidine in urine and its application for bioequivalence decision for ranitidine tablet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863299/),,0.67,174651,DB00863,Ranitidine
,11863299,recovery,The average recovery of ranitidine from urine was 89.35%.,Development of a sensitive high-performance thin-layer chromatography method for estimation of ranitidine in urine and its application for bioequivalence decision for ranitidine tablet formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863299/),%,89.35,174652,DB00863,Ranitidine
,11863299,relative bioavailability,"The relative bioavailability of Formulation 2 with respect to Formulation 1 was 93.76 and 95.31% on the basis of AUC0-24 and cumulative amount excreted, respectively.",Development of a sensitive high-performance thin-layer chromatography method for estimation of ranitidine in urine and its application for bioequivalence decision for ranitidine tablet formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863299/),%,93.76,174653,DB00863,Ranitidine
,11863299,relative bioavailability,"The relative bioavailability of Formulation 2 with respect to Formulation 1 was 93.76 and 95.31% on the basis of AUC0-24 and cumulative amount excreted, respectively.",Development of a sensitive high-performance thin-layer chromatography method for estimation of ranitidine in urine and its application for bioequivalence decision for ranitidine tablet formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863299/),%,95.31,174654,DB00863,Ranitidine
,8569424,time to 50% emptying,"With ranitidine, we found an acceleration of gastric emptying in 7 of 8 subjects, with 20% shortening of the time to 50% emptying (51.8 +/- 4.1 min vs 64.3 +/- 3.4, without ranitidine; P < .001 by paired t test).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),min,51.8,174842,DB00863,Ranitidine
,8569424,time to 50% emptying,"With ranitidine, we found an acceleration of gastric emptying in 7 of 8 subjects, with 20% shortening of the time to 50% emptying (51.8 +/- 4.1 min vs 64.3 +/- 3.4, without ranitidine; P < .001 by paired t test).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),,64.3,174843,DB00863,Ranitidine
,8569424,first pass metabolism,"As a result, after oral but not intravenous alcohol administration, ranitidine increased blood alcohol concentrations (29 +/- 4 mg/dl vs 22 +/- 3, without ranitidine; P < .02), with a corresponding decrease in first pass metabolism of ethanol from 107 +/- 16 mg/kg to 47 +/- 16 (P < .01).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),[mg] / [kg],107,174844,DB00863,Ranitidine
,8569424,first pass metabolism,"As a result, after oral but not intravenous alcohol administration, ranitidine increased blood alcohol concentrations (29 +/- 4 mg/dl vs 22 +/- 3, without ranitidine; P < .02), with a corresponding decrease in first pass metabolism of ethanol from 107 +/- 16 mg/kg to 47 +/- 16 (P < .01).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),,47,174845,DB00863,Ranitidine
,2178854,gastric residence time,"The mean (+/- SD) gastric residence time of the Heidelberg capsule was significantly decreased after both single and multiple doses of ranitidine compared to placebo (3.1 +/- 0.9 versus 3.8 +/- 1.1 hours, p less than 0.02; and 2.9 +/- 0.74 versus 3.9 +/- 0.9 hours, p less than 0.005, n = 9).",Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178854/),h,3.1,175055,DB00863,Ranitidine
,2178854,gastric residence time,"The mean (+/- SD) gastric residence time of the Heidelberg capsule was significantly decreased after both single and multiple doses of ranitidine compared to placebo (3.1 +/- 0.9 versus 3.8 +/- 1.1 hours, p less than 0.02; and 2.9 +/- 0.74 versus 3.9 +/- 0.9 hours, p less than 0.005, n = 9).",Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178854/),h,3.8,175056,DB00863,Ranitidine
,2178854,gastric residence time,"The mean (+/- SD) gastric residence time of the Heidelberg capsule was significantly decreased after both single and multiple doses of ranitidine compared to placebo (3.1 +/- 0.9 versus 3.8 +/- 1.1 hours, p less than 0.02; and 2.9 +/- 0.74 versus 3.9 +/- 0.9 hours, p less than 0.005, n = 9).",Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178854/),h,2.9,175057,DB00863,Ranitidine
,2178854,gastric residence time,"The mean (+/- SD) gastric residence time of the Heidelberg capsule was significantly decreased after both single and multiple doses of ranitidine compared to placebo (3.1 +/- 0.9 versus 3.8 +/- 1.1 hours, p less than 0.02; and 2.9 +/- 0.74 versus 3.9 +/- 0.9 hours, p less than 0.005, n = 9).",Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178854/),h,3.9,175058,DB00863,Ranitidine
not exceed,8864319,Peak plasma concentrations,"Peak plasma concentrations did not exceed 19 ng ml-1, remaining well below those associated with bismuth toxicity.",Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864319/),[ng] / [ml],19,175870,DB00863,Ranitidine
,8864319,terminal half-lives,"Plasma bismuth concentration-time data and urinary excretion data were best described by separate multicompartmental models, with terminal half-lives averaging 21 days and 45 days, respectively.",Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864319/),d,21,175871,DB00863,Ranitidine
,8864319,terminal half-lives,"Plasma bismuth concentration-time data and urinary excretion data were best described by separate multicompartmental models, with terminal half-lives averaging 21 days and 45 days, respectively.",Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864319/),d,45,175872,DB00863,Ranitidine
,22345389,flow rate,The flow rate was 1.2 mL/min.,A sensitive and rapid determination of ranitidine in human plasma by HPLC with fluorescence detection and its application for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345389/),[ml] / [min],1.2,178311,DB00863,Ranitidine
,22345389,recovery,The mean recovery was determined to be 96.40 ± 0.02%.,A sensitive and rapid determination of ranitidine in human plasma by HPLC with fluorescence detection and its application for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345389/),%,96.40,178312,DB00863,Ranitidine
,19858252,apparent clearance,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),[l] / [h],75.8,179515,DB00863,Ranitidine
,19858252,apparent volume being distribution,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,835,179516,DB00863,Ranitidine
,19858252,volume of distribution,"Among the covariates tested, significant effects were found for age (decrease in the volume of distribution of 123 liters per year of age) and the presence of diarrhea (59% loss of bioavailability).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,123,179517,DB00863,Ranitidine
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB00863,Ranitidine
,16863482,bioavailability,"Compared with treatment C (control), saquinavir's bioavailability was 15.9% (90% confidence interval [CI] 10-25%) after treatment A and 167% (90% CI 106-265%) after treatment B.",Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16863482/),%,15.9,180955,DB00863,Ranitidine
,16863482,bioavailability,"Compared with treatment C (control), saquinavir's bioavailability was 15.9% (90% confidence interval [CI] 10-25%) after treatment A and 167% (90% CI 106-265%) after treatment B.",Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16863482/),%,167,180956,DB00863,Ranitidine
,1563210,clearance,Burned patients exhibited significantly higher (p less than 0.01) ranitidine clearance (mean +/- SD; 10.80 +/- 2.38 versus 7.53 +/- 1.71 ml/min/kg) and steady-state distribution volume (1.63 +/- 0.13 versus 1.16 +/- 0.33 L/kg).,Pharmacokinetics and pharmacodynamics of ranitidine after burn injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563210/),[ml] / [kg·min],10.80,184622,DB00863,Ranitidine
,1563210,clearance,Burned patients exhibited significantly higher (p less than 0.01) ranitidine clearance (mean +/- SD; 10.80 +/- 2.38 versus 7.53 +/- 1.71 ml/min/kg) and steady-state distribution volume (1.63 +/- 0.13 versus 1.16 +/- 0.33 L/kg).,Pharmacokinetics and pharmacodynamics of ranitidine after burn injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563210/),[ml] / [kg·min],7.53,184623,DB00863,Ranitidine
,1563210,steady-state distribution volume,Burned patients exhibited significantly higher (p less than 0.01) ranitidine clearance (mean +/- SD; 10.80 +/- 2.38 versus 7.53 +/- 1.71 ml/min/kg) and steady-state distribution volume (1.63 +/- 0.13 versus 1.16 +/- 0.33 L/kg).,Pharmacokinetics and pharmacodynamics of ranitidine after burn injury. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563210/),[l] / [kg],1.63,184624,DB00863,Ranitidine
,1563210,steady-state distribution volume,Burned patients exhibited significantly higher (p less than 0.01) ranitidine clearance (mean +/- SD; 10.80 +/- 2.38 versus 7.53 +/- 1.71 ml/min/kg) and steady-state distribution volume (1.63 +/- 0.13 versus 1.16 +/- 0.33 L/kg).,Pharmacokinetics and pharmacodynamics of ranitidine after burn injury. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563210/),[l] / [kg],1.16,184625,DB00863,Ranitidine
,15624028,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 1503.9 ng/ml (diclofenac alone) and 1742.5 ng/ml (diclofenac and ranitidine).",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[ng] / [ml],1503.9,184954,DB00863,Ranitidine
,15624028,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 1503.9 ng/ml (diclofenac alone) and 1742.5 ng/ml (diclofenac and ranitidine).",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[ng] / [ml],1742.5,184955,DB00863,Ranitidine
,15624028,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 0.85 hrs, and 0.82 hrs, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),h,0.85,184956,DB00863,Ranitidine
,15624028,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 0.85 hrs, and 0.82 hrs, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),h,0.82,184957,DB00863,Ranitidine
,15624028,areas under the curve (AUC0-6),"The areas under the curve (AUC0-6) were 1479.9 ng x hr/ml and 1650.3 ng x hr/ml, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[h·ng] / [ml],1479.9,184958,DB00863,Ranitidine
,15624028,areas under the curve (AUC0-6),"The areas under the curve (AUC0-6) were 1479.9 ng x hr/ml and 1650.3 ng x hr/ml, respectively.",No effect of short term ranitidine intake on diclofenac pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15624028/),[h·ng] / [ml],1650.3,184959,DB00863,Ranitidine
,7550967,flow-rate,"The mobile phase was delivered at a flow-rate of 0.9 ml/min, detection was by ultraviolet absorption at 228 nm and concentrations were calculated on the basis of peak areas.",Determination of cimetidine in human plasma by high-performance liquid chromatography following liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550967/),[ml] / [min],0.9,185845,DB00863,Ranitidine
,23016949,total clearance,"Final parameter estimates for the population were 32.1 l h(-1) for total clearance and 285 l for volume of distribution, both allometrically modelled for a 70 kg adult.",Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016949/),[l] / [h],32.1,187337,DB00863,Ranitidine
,23016949,volume of distribution,"Final parameter estimates for the population were 32.1 l h(-1) for total clearance and 285 l for volume of distribution, both allometrically modelled for a 70 kg adult.",Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016949/),l,285,187338,DB00863,Ranitidine
,23016949,absorption rate constant,"Final estimates for absorption rate constant and bioavailability were 1.31 h(-1) and 27.5%, respectively.",Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016949/),1/[h],1.31,187339,DB00863,Ranitidine
,23016949,bioavailability,"Final estimates for absorption rate constant and bioavailability were 1.31 h(-1) and 27.5%, respectively.",Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016949/),%,27.5,187340,DB00863,Ranitidine
,12434565,Cmax,"The area under the curve (AUC) was 30% greater in WOF, Cmax was 921.5 ng/ml (WF) vs. 1685.2 (WOF), and t1/2 was 2.70 +/- 1.38 (WF) h vs 3.66 +/- 1.34 (WOF).",Bioavailability of ranitidine in healthy Mexican volunteers: effect of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12434565/),[ng] / [ml],921.5,187357,DB00863,Ranitidine
,12434565,Cmax,"The area under the curve (AUC) was 30% greater in WOF, Cmax was 921.5 ng/ml (WF) vs. 1685.2 (WOF), and t1/2 was 2.70 +/- 1.38 (WF) h vs 3.66 +/- 1.34 (WOF).",Bioavailability of ranitidine in healthy Mexican volunteers: effect of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12434565/),,1685.2,187358,DB00863,Ranitidine
,12434565,t1/2,"The area under the curve (AUC) was 30% greater in WOF, Cmax was 921.5 ng/ml (WF) vs. 1685.2 (WOF), and t1/2 was 2.70 +/- 1.38 (WF) h vs 3.66 +/- 1.34 (WOF).",Bioavailability of ranitidine in healthy Mexican volunteers: effect of food. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12434565/),h,2.70,187359,DB00863,Ranitidine
,12434565,t1/2,"The area under the curve (AUC) was 30% greater in WOF, Cmax was 921.5 ng/ml (WF) vs. 1685.2 (WOF), and t1/2 was 2.70 +/- 1.38 (WF) h vs 3.66 +/- 1.34 (WOF).",Bioavailability of ranitidine in healthy Mexican volunteers: effect of food. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12434565/),,3.66,187360,DB00863,Ranitidine
,6305671,t1/2 beta,"The drug followed a two-compartment model, with mean values for t1/2 beta, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively.",The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),min,80,190251,DB00863,Ranitidine
,6305671,volume of distribution steady-state,"The drug followed a two-compartment model, with mean values for t1/2 beta, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively.",The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),[ml] / [min],701,190252,DB00863,Ranitidine
,6305671,total plasma clearance,"The drug followed a two-compartment model, with mean values for t1/2 beta, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively.",The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),[ml] / [min],680,190253,DB00863,Ranitidine
,6305671,oral bioavailability,The oral bioavailability of ranitidine in these 5 patients showed wide variation (27-76%; mean 51%).,The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),%,51,190254,DB00863,Ranitidine
,8116940,area under the concentration vs time curve,"Dosage of 0.25 mg/kg induced approximately half-maximal inhibition of basal gastric pH in these ponies and was associated with area under the concentration vs time curve of 0.7 mumol.h/L, which corresponds reasonably with results of other species.",Effects of single intravenously administered doses of omeprazole and ranitidine on intragastric pH and plasma gastrin concentration in nonfed ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116940/),[h·μM] / [l],0.7,193918,DB00863,Ranitidine
,2905250,duration of effect,The duration of effect was approximately 12 hours.,"The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905250/),h,12,193937,DB00863,Ranitidine
,11839657,central volume of distribution,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),[l] / [m(2],1.45,195160,DB00863,Ranitidine
,11839657,clearance,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),[h·l] / [m(2],0.03,195161,DB00863,Ranitidine
,11839657,elimination half-life,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),h,36.4,195162,DB00863,Ranitidine
,8803904,bioavailability,Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0.7-0.8 bioavailability) when given orally.,Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),,0.7-0.8,195382,DB00863,Ranitidine
,8803904,half-lives,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),d,40 and 50,195383,DB00863,Ranitidine
,8803904,blood clearance,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),[ml] / [min],96,195384,DB00863,Ranitidine
,8803904,Protein binding,"Protein binding ranges between 30 and 40% with binding to both albumin and alpha, glycoprotein.",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),%,30 and 40,195385,DB00863,Ranitidine
,2892249,plasma half-life,The plasma half-life in each of the animal species was between 1 and 2 h and no accumulation of nizatidine or its metabolites was seen in rats or dogs after daily oral administration for long periods.,Pharmacology and toxicology of nizatidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892249/),h,1 and 2,195724,DB00863,Ranitidine
,9218931,renal clearance,"Ranitidine renal clearance, ranging from 0 to 1003 m1.min-1, correlated with CPAH (r2 = 0.707), while non-renal clearance was unaltered.",Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218931/),[m1] / [min],0 to 1003,195782,DB00863,Ranitidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,35.3,195854,DB00863,Ranitidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,37.3,195855,DB00863,Ranitidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],28.2,195856,DB00863,Ranitidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],26.7,195857,DB00863,Ranitidine
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,21,195947,DB00863,Ranitidine
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,24,195948,DB00863,Ranitidine
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,186,196917,DB00863,Ranitidine
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,482,196918,DB00863,Ranitidine
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,134,196919,DB00863,Ranitidine
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,35,196920,DB00863,Ranitidine
,31542894,renal clearance,"Instead, renal clearance was lowered by ∼15% (530 ± 99 vs 460 ± 120 mL/min; P < .05).",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),[ml] / [min],530,196921,DB00863,Ranitidine
,31542894,renal clearance,"Instead, renal clearance was lowered by ∼15% (530 ± 99 vs 460 ± 120 mL/min; P < .05).",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),[ml] / [min],460,196922,DB00863,Ranitidine
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,7.05,198297,DB00863,Ranitidine
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,7.43,198298,DB00863,Ranitidine
,27292271,serum elimination half-life,"The serum elimination half-life was 7.05 ± 1.02, 7.43 ± 0.851 and 3.94 ± 1.04 h for cimetidine, ranitidine, and omeprazole, respectively.","Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27292271/),h,3.94,198299,DB00863,Ranitidine
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],38.6,198791,DB00863,Ranitidine
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],6.0,198792,DB00863,Ranitidine
,3197752,distribution,"The mean distribution and elimination half lives were 0.13 and 2.57 h, respectively.",Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),h,0.13,199299,DB00863,Ranitidine
,3197752,elimination half lives,"The mean distribution and elimination half lives were 0.13 and 2.57 h, respectively.",Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),h,2.57,199300,DB00863,Ranitidine
,3197752,total body clearance (CL),"The total body clearance (CL) and volume of distribution (Vz) were 298 ml.min-1 (5.19 ml.min-1.kg-1) and 1.08 l.kg-1, respectively.",Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),[ml] / [min],298,199301,DB00863,Ranitidine
,3197752,volume of distribution (Vz),"The total body clearance (CL) and volume of distribution (Vz) were 298 ml.min-1 (5.19 ml.min-1.kg-1) and 1.08 l.kg-1, respectively.",Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),[ml] / [kg·min],5.19,199302,DB00863,Ranitidine
,3197752,volume of distribution (Vz),"The total body clearance (CL) and volume of distribution (Vz) were 298 ml.min-1 (5.19 ml.min-1.kg-1) and 1.08 l.kg-1, respectively.",Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),[l] / [kg],1.08,199303,DB00863,Ranitidine
,3197752,clearance,The haemofiltration clearance was 66.9 ml.min-1 at a filtrate flow rate of 86 ml.,Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),[ml] / [min],66.9,199304,DB00863,Ranitidine
,3197752,filtrate flow rate,The haemofiltration clearance was 66.9 ml.min-1 at a filtrate flow rate of 86 ml.,Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),ml,86,199305,DB00863,Ranitidine
,3197752,sieving coefficient,"min-1, corresponding to a mean sieving coefficient of 0.78 (n = 6).",Pharmacokinetics of ranitidine in patients undergoing haemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197752/),,0.78,199306,DB00863,Ranitidine
,2905709,area under the concentration-time curve,"After a 400-mg oral dose of tocainide, the area under the concentration-time curve decreased from (mean +/- SD) 31.64 +/- 14.16 micrograms.hr/mL during placebo, to 23.10 +/- 7.33 micrograms.hr/mL during cimetidine (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[h·μg] / [ml],31.64,201770,DB00863,Ranitidine
,2905709,area under the concentration-time curve,"After a 400-mg oral dose of tocainide, the area under the concentration-time curve decreased from (mean +/- SD) 31.64 +/- 14.16 micrograms.hr/mL during placebo, to 23.10 +/- 7.33 micrograms.hr/mL during cimetidine (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[h·μg] / [ml],23.10,201771,DB00863,Ranitidine
,2905709,peak tocainide concentrations,"Similarly, the peak tocainide concentrations were 2.81 +/- 0.89 micrograms/mL and 1.70 +/- 0.44 micrograms/mL with placebo and cimetidine, respectively (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[μg] / [ml],2.81,201772,DB00863,Ranitidine
,2905709,peak tocainide concentrations,"Similarly, the peak tocainide concentrations were 2.81 +/- 0.89 micrograms/mL and 1.70 +/- 0.44 micrograms/mL with placebo and cimetidine, respectively (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[μg] / [ml],1.70,201773,DB00863,Ranitidine
,2905709,total amount,"However, the total amount of tocainide excreted unchanged in the urine, decreased from 159.8 +/- 14.7 mg with placebo to 136.8 +/- 26.8 mg with cimetidine (P less than .05), whereas there was no change with ranitidine.",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),,159,201774,DB00863,Ranitidine
,2905709,total amount,"However, the total amount of tocainide excreted unchanged in the urine, decreased from 159.8 +/- 14.7 mg with placebo to 136.8 +/- 26.8 mg with cimetidine (P less than .05), whereas there was no change with ranitidine.",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),,136,201775,DB00863,Ranitidine
,3378388,apparent oral clearance (dose/AUC),"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],66,201963,DB00863,Ranitidine
,3378388,apparent oral clearance (dose/AUC),"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],33,201964,DB00863,Ranitidine
,3378388,elimination half-life,"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),h,4.0,201965,DB00863,Ranitidine
,3378388,elimination half-life,"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),h,4.9,201966,DB00863,Ranitidine
,3378388,apparent oral clearance,"During nifedipine multiple-dose administration, cimetidine decreased the apparent oral clearance from 76 +/- 39 to 43 +/- 20 L/hr (p less than 0.01).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],76,201967,DB00863,Ranitidine
,3378388,apparent oral clearance,"During nifedipine multiple-dose administration, cimetidine decreased the apparent oral clearance from 76 +/- 39 to 43 +/- 20 L/hr (p less than 0.01).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],43,201968,DB00863,Ranitidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],18,201969,DB00863,Ranitidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],9,201970,DB00863,Ranitidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],18,201971,DB00863,Ranitidine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],13,201972,DB00863,Ranitidine
,15487653,half-life,Zinc levels in the plasma declined in a steady fashion (half-life = 7.6 d).,Diagnosis and treatment of zinc poisoning in a dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487653/),d,7.6,201996,DB00863,Ranitidine
,3653228,distribution,"The mean +/- SD distribution and elimination rate constants were 2.47 +/- 0.78 and 0.098 +/- 0.013 h, respectively.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),h,2.47,205605,DB00863,Ranitidine
,3653228,elimination rate constants,"The mean +/- SD distribution and elimination rate constants were 2.47 +/- 0.78 and 0.098 +/- 0.013 h, respectively.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),h,0.098,205606,DB00863,Ranitidine
,3653228,area under the serum concentration vs time curve,"The area under the serum concentration vs time curve after the i.v. dose was 5979 +/- 2870 micrograms X h X l-1, resulting in a mean volume of distribution of 76.8 l and a total body clearance of 126 ml X min-1.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[h·μg] / [l],5979,205607,DB00863,Ranitidine
,3653228,volume of distribution,"The area under the serum concentration vs time curve after the i.v. dose was 5979 +/- 2870 micrograms X h X l-1, resulting in a mean volume of distribution of 76.8 l and a total body clearance of 126 ml X min-1.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),l,76.8,205608,DB00863,Ranitidine
,3653228,total body clearance,"The area under the serum concentration vs time curve after the i.v. dose was 5979 +/- 2870 micrograms X h X l-1, resulting in a mean volume of distribution of 76.8 l and a total body clearance of 126 ml X min-1.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[ml] / [min],126,205609,DB00863,Ranitidine
,3653228,observed maximum plasma concentration,"Following oral administration the observed maximum plasma concentration was 904 +/- 483 micrograms X l-1 at 4.2 +/- 1.8 h, and the bioavailability was 69.7 +/- 35.6%.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[μg] / [l],904,205610,DB00863,Ranitidine
,3653228,bioavailability,"Following oral administration the observed maximum plasma concentration was 904 +/- 483 micrograms X l-1 at 4.2 +/- 1.8 h, and the bioavailability was 69.7 +/- 35.6%.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),%,69.7,205611,DB00863,Ranitidine
,3653228,peritoneal clearance,"The peritoneal clearance of ranitidine was 3.2 +/- 0.7 and 2.6 +/- 0.6 ml X min-1 for the i.v. and oral groups, respectively.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[ml] / [min],3.2,205612,DB00863,Ranitidine
,3653228,peritoneal clearance,"The peritoneal clearance of ranitidine was 3.2 +/- 0.7 and 2.6 +/- 0.6 ml X min-1 for the i.v. and oral groups, respectively.",Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[ml] / [min],2.6,205613,DB00863,Ranitidine
,3653228,amount of drug removed,The amount of drug removed by dialysis was 561.2 +/- 336.2 micrograms for the i.v. and 1197.1 +/- 602.3 micrograms for the oral group.,Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),μg,561.2,205614,DB00863,Ranitidine
,3653228,amount of drug removed,The amount of drug removed by dialysis was 561.2 +/- 336.2 micrograms for the i.v. and 1197.1 +/- 602.3 micrograms for the oral group.,Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),μg,1197.1,205615,DB00863,Ranitidine
,3653228,renal ranitidine clearance,Four patients in the i.v. group had urine output during the study period with renal ranitidine clearance values of 9.9 +/- 9.9 ml X min-1.,Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[ml] / [min],9.9,205616,DB00863,Ranitidine
,3653228,renal ranitidine clearance,Two patients in the oral group had urine output and corresponding renal ranitidine clearance values of 5.1 and 20.1 ml X min-1.,Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[ml] / [min],5.1,205617,DB00863,Ranitidine
,3653228,renal ranitidine clearance,Two patients in the oral group had urine output and corresponding renal ranitidine clearance values of 5.1 and 20.1 ml X min-1.,Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653228/),[ml] / [min],20.1,205618,DB00863,Ranitidine
,1487550,maximum peak plasma concentration (Cmax),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[μg] / [ml],1.53,207156,DB00863,Ranitidine
,1487550,time to peak concentration (Tmax),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,7.5,207157,DB00863,Ranitidine
,1487550,t1/2a,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,1.38,207158,DB00863,Ranitidine
,1487550,t1/2el,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,53.3,207159,DB00863,Ranitidine
,1487550,Cl/F,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[ml] / [min],2.98,207160,DB00863,Ranitidine
,1487550,volume of distribution (Vd/F),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),l,13.2,207161,DB00863,Ranitidine
,1487550,area under the curve (AUC),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[μg] / [h·ml],117.6,207162,DB00863,Ranitidine
,2467982,CLR,Mean +/- S.D. base-line procainamide CLR was 539 +/- 114 ml/min for Group I vs. 410 +/- 61 ml/min for Group II (P less than .01).,Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467982/),[ml] / [min],539,208716,DB00863,Ranitidine
,2467982,CLR,Mean +/- S.D. base-line procainamide CLR was 539 +/- 114 ml/min for Group I vs. 410 +/- 61 ml/min for Group II (P less than .01).,Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467982/),[ml] / [min],410,208717,DB00863,Ranitidine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.74,209186,DB00863,Ranitidine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.81,209187,DB00863,Ranitidine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.70,209188,DB00863,Ranitidine
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,35.3,211889,DB00863,Ranitidine
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,30.1,211890,DB00863,Ranitidine
,2890666,terminal half-life,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),h,37.3,211891,DB00863,Ranitidine
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],28.2,211892,DB00863,Ranitidine
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],26.5,211893,DB00863,Ranitidine
,2890666,total plasma clearance,Neither ranitidine nor nizatidine had any significant effect on the hepatic elimination of D as characterized by its terminal half-life (mean +/- SD) of 35.3 +/- 24.2 hours (+ ranitidine: 30.1 +/- 9.9 hr; + nizatidine: 37.3 +/- 18.3 hr) or total plasma clearance of 28.2 +/- 12.0 mL/min (+ ranitidine: 26.5 +/- 7.9 mL/min; + nizatidine: 26.7 +/- 10.4 mL/min).,Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890666/),[ml] / [min],26.7,211894,DB00863,Ranitidine
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],4.55,212272,DB00863,Ranitidine
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],4.78,212273,DB00863,Ranitidine
,3240766,oral clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],3.58,212274,DB00863,Ranitidine
,3240766,clearance,"The oral clearance of theophylline after ranitidine pretreatment, 4.55 +/- 1.69 l/h (mean +/- SD) was indistinguishable from that after placebo, 4.78 +/- 1.96 l/h, but cimetidine was associated with a significant 21% reduction in theophylline clearance, 3.58 +/- 1.07 l/h (P = 0.006).",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),[l] / [h],3.58,212275,DB00863,Ranitidine
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,6.11,212276,DB00863,Ranitidine
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,5.05,212277,DB00863,Ranitidine
,3240766,terminal half-life,"There was a correspondingly significant increase in the terminal half-life of theophylline following cimetidine, 6.11 +/- 1.29 h (P = 0.017), compared with 5.05 +/- 1.43 h and 4.88 +/- 1.45 h for placebo and ranitidine, respectively.",The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240766/),h,4.88,212278,DB00863,Ranitidine
,1982764,maximum plasma concentration (Cmax),The mean maximum plasma concentration (Cmax) was 467 ng.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),ng,467,212417,DB00863,Ranitidine
,1982764,area under the plasma concentration vs time curve (AUC),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·ng] / [ml],2460,212418,DB00863,Ranitidine
,1982764,area under the plasma concentration vs time curve (AUC),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·ng] / [ml],2551,212419,DB00863,Ranitidine
,1982764,terminal half-life (t 1/2),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,3.6,212420,DB00863,Ranitidine
,1982764,terminal half-life (t 1/2),ml-1 in the presence of piroxicam: mean area under the plasma concentration vs time curve (AUC) was 2460 h.ng ml-1 and 2551 h.ng ml-1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,3.8,212421,DB00863,Ranitidine
,1982764,Cmax,The mean Cmax was 2.1 micrograms.,A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),μg,2.1,212422,DB00863,Ranitidine
,1982764,AUC,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·μg] / [ml],133,212423,DB00863,Ranitidine
,1982764,AUC,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),[h·μg] / [ml],137,212424,DB00863,Ranitidine
,1982764,t 1/2,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,53.6,212425,DB00863,Ranitidine
,1982764,t 1/2,"ml-1 in the presence of ranitidine respectively; mean AUC was 133 h.microgram ml-1 and 137 h.microgram ml-1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.",A lack of pharmacokinetic interaction between ranitidine and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982764/),h,54.5,212426,DB00863,Ranitidine
,6105117,elimination half-life,The estimated elimination half-life was 140 minutes and the bioavailability of the oral drug was about 50%.,Ranitidine--a new H2-receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105117/),min,140,214329,DB00863,Ranitidine
,6105117,bioavailability,The estimated elimination half-life was 140 minutes and the bioavailability of the oral drug was about 50%.,Ranitidine--a new H2-receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105117/),%,50,214330,DB00863,Ranitidine
,1914362,bioavailability,"When ddI was given to fasting patients as an oral solution with antacid, the bioavailability was 41% +/- 7% (mean +/- SEM).","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,41,222567,DB00863,Ranitidine
,1914362,bioavailability,"However, when given as buffered tablets, the bioavailability was considerably less (25% +/- 5%).","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,25,222568,DB00863,Ranitidine
,1914362,bioavailability,The bioavailability increased slightly when the tablets were given with supplemental antacid (36% +/- 6%).,"Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,36,222569,DB00863,Ranitidine
,1914362,bioavailability,"Two enteric-coated preparations had reasonable bioavailability (36% +/- 5% and 26% +/- 5%), but the peak plasma level was much lower and occurred at a much later time than with the oral solution.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,36,222570,DB00863,Ranitidine
,1914362,bioavailability,"Two enteric-coated preparations had reasonable bioavailability (36% +/- 5% and 26% +/- 5%), but the peak plasma level was much lower and occurred at a much later time than with the oral solution.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,26,222571,DB00863,Ranitidine
,1914362,bioavailability,"When ddI was given as a premeasured powder containing sucrose and buffer to be reconstituted by the patient (the ""sachet"" preparation), the bioavailability was 29% +/- 6%.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,29,222572,DB00863,Ranitidine
,1914362,bioavailability,"However, the bioavailability of the sachet was only 17% +/- 4% when administered with food.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,17,222573,DB00863,Ranitidine
,1600045,peak plasma alcohol concentration,"h/dL, respectively, P = 0.07), and a statistically significant increase in mean peak plasma alcohol concentration after dosing with ranitidine (4.92 and 6.47 mg/dL, respectively, P = 0.05).",Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600045/),[mg] / [dl],4.92,223750,DB00863,Ranitidine
,1600045,peak plasma alcohol concentration,"h/dL, respectively, P = 0.07), and a statistically significant increase in mean peak plasma alcohol concentration after dosing with ranitidine (4.92 and 6.47 mg/dL, respectively, P = 0.05).",Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600045/),[mg] / [dl],6.47,223751,DB00863,Ranitidine
,12182252,absolute bioavailability,The absolute bioavailability of rosiglitazone was 99%.,The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182252/),%,99,224207,DB00863,Ranitidine
,12182252,absolute bioavailability,"In this study of 12 healthy adult male volunteers, the absolute bioavailability of rosiglitazone was 99%, and the oral and IV single-dose pharmacokinetics of rosiglitazone were unaltered by concurrent treatment with ranitidine.",The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182252/),%,99,224208,DB00863,Ranitidine
,7944484,maximum tolerated dose,The maximum tolerated dose was 200 mg/m2.,[Phase I study of paclitaxel]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),[mg] / [m],200,224512,DB00863,Ranitidine
,7944484,half-life,The paclitaxel plasma concentration declined with a half-life of 10.0 to 24.9 hours.,[Phase I study of paclitaxel]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),h,10.0 to 24.9,224513,DB00863,Ranitidine
,7944484,Excretion into urine,Excretion into urine within 72 hours was in the range of 7.28 to 11.34% of paclitaxel dosage.,[Phase I study of paclitaxel]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),%,7.28 to 11.34,224514,DB00863,Ranitidine
,2923963,half-life,"The control mean theophylline half-life and clearance were 7.32 h and 0.86 ml min-1 kg-1, respectively.",Effects of equimolar doses of cimetidine and ranitidine on theophylline elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923963/),h,7.32,225219,DB00863,Ranitidine
,2923963,clearance,"The control mean theophylline half-life and clearance were 7.32 h and 0.86 ml min-1 kg-1, respectively.",Effects of equimolar doses of cimetidine and ranitidine on theophylline elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2923963/),[ml] / [kg·min],0.86,225220,DB00863,Ranitidine
,6127399,steady-state concentration (CMss),"Following maternal dosage, the mean maternal (jugular vein) steady-state concentration (CMss) at 4 hr was 842 +/- 66 ng/ml (SEM), the mean fetal (carotid artery) steady-state concentration (CFss) was 26.5 +/- 4.2 ng/ml, and the mean fetal umbilical venous steady-state concentration was 28.9 +/- 3.5 ng/ml.",Placental transfer of ranitidine during steady-state infusions of maternal and fetal sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127399/),[ng] / [ml],842,226651,DB00863,Ranitidine
,6127399,steady-state concentration (CFss),"Following maternal dosage, the mean maternal (jugular vein) steady-state concentration (CMss) at 4 hr was 842 +/- 66 ng/ml (SEM), the mean fetal (carotid artery) steady-state concentration (CFss) was 26.5 +/- 4.2 ng/ml, and the mean fetal umbilical venous steady-state concentration was 28.9 +/- 3.5 ng/ml.",Placental transfer of ranitidine during steady-state infusions of maternal and fetal sheep. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127399/),[ng] / [ml],26.5,226652,DB00863,Ranitidine
,6127399,steady-state concentration,"Following maternal dosage, the mean maternal (jugular vein) steady-state concentration (CMss) at 4 hr was 842 +/- 66 ng/ml (SEM), the mean fetal (carotid artery) steady-state concentration (CFss) was 26.5 +/- 4.2 ng/ml, and the mean fetal umbilical venous steady-state concentration was 28.9 +/- 3.5 ng/ml.",Placental transfer of ranitidine during steady-state infusions of maternal and fetal sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127399/),[ng] / [ml],28.9,226653,DB00863,Ranitidine
,6127399,CMss,"With fetal dosage, mean CMss was 414 +/- 42 ng/ml at 4 hr and was significantly less than the mean CFss value at the same time, which was 6890 +/- 360 ng/ml (p less than 0.005).",Placental transfer of ranitidine during steady-state infusions of maternal and fetal sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127399/),[ng] / [ml],414,226654,DB00863,Ranitidine
,6127399,CFss,"With fetal dosage, mean CMss was 414 +/- 42 ng/ml at 4 hr and was significantly less than the mean CFss value at the same time, which was 6890 +/- 360 ng/ml (p less than 0.005).",Placental transfer of ranitidine during steady-state infusions of maternal and fetal sheep. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127399/),[ng] / [ml],6890,226655,DB00863,Ranitidine
,11966498,Cmax,"The estimated pharmacokinetic parameters of ranitidine, 75 mg, were as follows: the median Cmax value of 477 ng/mL occurred within a median of 2.5 h after dosing, and the median half-life was 2.0 h.","Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966498/),[ng] / [ml],477,227843,DB00863,Ranitidine
,11966498,half-life,"The estimated pharmacokinetic parameters of ranitidine, 75 mg, were as follows: the median Cmax value of 477 ng/mL occurred within a median of 2.5 h after dosing, and the median half-life was 2.0 h.","Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966498/),h,2.0,227844,DB00863,Ranitidine
,20080374,m/,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,292.2,233631,DB00863,Ranitidine
,20080374,m/z,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,308.2,233632,DB00863,Ranitidine
,20080374,m/z,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,315.3,233633,DB00863,Ranitidine
,20080374,m/z,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,176.2,233634,DB00863,Ranitidine
,12868543,distribution volume (Vd),"Comparison of the pharmacokinetic parameters of women and men revealed statistically significant differences both in distribution volume (Vd) with values of 2.0 and 6.3 l/kg, Area Under Curve (AUC) with values of 7312.15 and 11471.94 ng/ml/h, and clearance (CLt) with values of 0.65 and 0.59 l/kg/h, respectively.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [kg],2.0,237848,DB00863,Ranitidine
,12868543,distribution volume (Vd),"Comparison of the pharmacokinetic parameters of women and men revealed statistically significant differences both in distribution volume (Vd) with values of 2.0 and 6.3 l/kg, Area Under Curve (AUC) with values of 7312.15 and 11471.94 ng/ml/h, and clearance (CLt) with values of 0.65 and 0.59 l/kg/h, respectively.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [kg],6.3,237849,DB00863,Ranitidine
,12868543,Area Under Curve (AUC),"Comparison of the pharmacokinetic parameters of women and men revealed statistically significant differences both in distribution volume (Vd) with values of 2.0 and 6.3 l/kg, Area Under Curve (AUC) with values of 7312.15 and 11471.94 ng/ml/h, and clearance (CLt) with values of 0.65 and 0.59 l/kg/h, respectively.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[ng] / [h·ml],7312.15,237850,DB00863,Ranitidine
,12868543,Area Under Curve (AUC),"Comparison of the pharmacokinetic parameters of women and men revealed statistically significant differences both in distribution volume (Vd) with values of 2.0 and 6.3 l/kg, Area Under Curve (AUC) with values of 7312.15 and 11471.94 ng/ml/h, and clearance (CLt) with values of 0.65 and 0.59 l/kg/h, respectively.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[ng] / [h·ml],11471.94,237851,DB00863,Ranitidine
,12868543,clearance (CLt),"Comparison of the pharmacokinetic parameters of women and men revealed statistically significant differences both in distribution volume (Vd) with values of 2.0 and 6.3 l/kg, Area Under Curve (AUC) with values of 7312.15 and 11471.94 ng/ml/h, and clearance (CLt) with values of 0.65 and 0.59 l/kg/h, respectively.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [h·kg],0.65,237852,DB00863,Ranitidine
,12868543,clearance (CLt),"Comparison of the pharmacokinetic parameters of women and men revealed statistically significant differences both in distribution volume (Vd) with values of 2.0 and 6.3 l/kg, Area Under Curve (AUC) with values of 7312.15 and 11471.94 ng/ml/h, and clearance (CLt) with values of 0.65 and 0.59 l/kg/h, respectively.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [h·kg],0.59,237853,DB00863,Ranitidine
,12868543,Vd,"Several pharmacokinetic parameters in women were different in the follicular compared to the luteal phase; for example, Vd was 2.0 and 5.6 l/kg, AUC was 7312.15 and 5195.83 ng/ml/h, and CLt was 0.65 and 0.97 l/kg/h, in the respective phases.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [kg],2.0,237854,DB00863,Ranitidine
,12868543,Vd,"Several pharmacokinetic parameters in women were different in the follicular compared to the luteal phase; for example, Vd was 2.0 and 5.6 l/kg, AUC was 7312.15 and 5195.83 ng/ml/h, and CLt was 0.65 and 0.97 l/kg/h, in the respective phases.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [kg],5.6,237855,DB00863,Ranitidine
,12868543,AUC,"Several pharmacokinetic parameters in women were different in the follicular compared to the luteal phase; for example, Vd was 2.0 and 5.6 l/kg, AUC was 7312.15 and 5195.83 ng/ml/h, and CLt was 0.65 and 0.97 l/kg/h, in the respective phases.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[ng] / [h·ml],7312.15,237856,DB00863,Ranitidine
,12868543,AUC,"Several pharmacokinetic parameters in women were different in the follicular compared to the luteal phase; for example, Vd was 2.0 and 5.6 l/kg, AUC was 7312.15 and 5195.83 ng/ml/h, and CLt was 0.65 and 0.97 l/kg/h, in the respective phases.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[ng] / [h·ml],5195.83,237857,DB00863,Ranitidine
,12868543,CLt,"Several pharmacokinetic parameters in women were different in the follicular compared to the luteal phase; for example, Vd was 2.0 and 5.6 l/kg, AUC was 7312.15 and 5195.83 ng/ml/h, and CLt was 0.65 and 0.97 l/kg/h, in the respective phases.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [h·kg],0.65,237858,DB00863,Ranitidine
,12868543,CLt,"Several pharmacokinetic parameters in women were different in the follicular compared to the luteal phase; for example, Vd was 2.0 and 5.6 l/kg, AUC was 7312.15 and 5195.83 ng/ml/h, and CLt was 0.65 and 0.97 l/kg/h, in the respective phases.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[l] / [h·kg],0.97,237859,DB00863,Ranitidine
,12868543,maximum concentration (Cmax),"Moreover, the maximum concentration (Cmax) was 1086 ng/ml in the follicular vs. 864 ng/ml in the luteal phase.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[ng] / [ml],1086,237860,DB00863,Ranitidine
,12868543,maximum concentration (Cmax),"Moreover, the maximum concentration (Cmax) was 1086 ng/ml in the follicular vs. 864 ng/ml in the luteal phase.",Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12868543/),[ng] / [ml],864,237861,DB00863,Ranitidine
,6323087,Terminal t1/2,Terminal t1/2 was 2.7 +/- 0.4 hr after oral dosing and 2.9 +/- 0.4 hr after intravenous injection.,Ranitidine disposition and systemic availability in hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6323087/),h,2.7,241236,DB00863,Ranitidine
,6323087,Terminal t1/2,Terminal t1/2 was 2.7 +/- 0.4 hr after oral dosing and 2.9 +/- 0.4 hr after intravenous injection.,Ranitidine disposition and systemic availability in hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6323087/),h,2.9,241237,DB00863,Ranitidine
,6323087,Total plasma clearance,Total plasma clearance was 470 +/- 170 ml/min and the steady-state volume of distribution was 1.2 +/- 0.2 l/kg.,Ranitidine disposition and systemic availability in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6323087/),[ml] / [min],470,241238,DB00863,Ranitidine
,6323087,steady-state volume of distribution,Total plasma clearance was 470 +/- 170 ml/min and the steady-state volume of distribution was 1.2 +/- 0.2 l/kg.,Ranitidine disposition and systemic availability in hepatic cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6323087/),[l] / [kg],1.2,241239,DB00863,Ranitidine
,6323087,Systemic availability,Systemic availability as assessed by AUC analysis was 58% +/- 11%.,Ranitidine disposition and systemic availability in hepatic cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6323087/),%,58,241240,DB00863,Ranitidine
,6323087,serum protein binding,At 0.5 microgram/ml the serum protein binding of ranitidine was 4.6% +/- 1.3%.,Ranitidine disposition and systemic availability in hepatic cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6323087/),%,4.6,241241,DB00863,Ranitidine
,15663296,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 730.8 ng/ml for omeprazole alone and 802.1 ng/ml for omeprazole co-administered with ranitidine (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[ng] / [ml],730.8,245645,DB00863,Ranitidine
,15663296,peak plasma concentrations Cmax,"In the two periods of treatments, the mean peak plasma concentrations Cmax were 730.8 ng/ml for omeprazole alone and 802.1 ng/ml for omeprazole co-administered with ranitidine (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[ng] / [ml],802.1,245646,DB00863,Ranitidine
,15663296,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.29 h and 1.42 h, respectively (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),h,1.29,245647,DB00863,Ranitidine
,15663296,"time taken to reach the peak, Tmax","The time taken to reach the peak, Tmax, was 1.29 h and 1.42 h, respectively (not significant).",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),h,1.42,245648,DB00863,Ranitidine
,15663296,areas under the curve (AUC0-10),"The areas under the curve (AUC0-10) were 1,453.3 ng.h/ml and 1,736.8 ng.h/ml for the two periods of treatment; thus a greater AUC was obtained after pretreatment with multiple doses of ranitidine.",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[h·ng] / [ml],"1,453.3",245649,DB00863,Ranitidine
,15663296,areas under the curve (AUC0-10),"The areas under the curve (AUC0-10) were 1,453.3 ng.h/ml and 1,736.8 ng.h/ml for the two periods of treatment; thus a greater AUC was obtained after pretreatment with multiple doses of ranitidine.",A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663296/),[h·ng] / [ml],"1,736.8",245650,DB00863,Ranitidine
,8519046,apparent oral clearance,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[l] / [h],2.47,246341,DB00863,Ranitidine
,8519046,apparent oral clearance,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[l] / [h],1.85,246342,DB00863,Ranitidine
,8519046,area under the curve,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [h·l],233.48,246343,DB00863,Ranitidine
,8519046,area under the curve,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [h·l],307.43,246344,DB00863,Ranitidine
,8519046,peak concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],13.2,246345,DB00863,Ranitidine
,8519046,peak concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],16.7,246346,DB00863,Ranitidine
,8519046,trough concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],6.4,246347,DB00863,Ranitidine
,8519046,trough concentration,"Coadministration of cimetidine, but not ranitidine, was associated with a significant decrease in the apparent oral clearance of theophylline (2.47 +/- 0.91 vs 1.85 +/- 0.63 L/hr; P = 0.004) and increases in the theophylline area under the curve (233.48 +/- 58.99 vs 307.43 +/- 79.07 mg/L/hr; P = 0.003), peak concentration (13.2 +/- 2.8 vs 16.7 +/- 3.7 mg/L; P = 0.002), and trough concentration (6.4 +/- 2.5 vs 9.0 +/- 3.0 mg/L; P = 0.008).",Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8519046/),[mg] / [l],9.0,246348,DB00863,Ranitidine
,1618254,peak blood ethanol concentration,The peak blood ethanol concentration of 21.9 to 22.8 mmol.l-1 occurred at 64 to 70 min after the end of drinking.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [l],21.9 to 22.8,255086,DB00863,Ranitidine
,1618254,rate of disappearance,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [h·l],3.0 to 3.3,255087,DB00863,Ranitidine
,1618254,rate of removal,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[g] / [h],8.0 to 8.5,255088,DB00863,Ranitidine
,1618254,apparent volume of distribution,"The apparent volume of distribution of ethanol was almost the same for all four treatments: mean 0.68 l.kg-1, corresponding to a mean total body water of 44 l (59% body weight).","Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[l] / [kg],0.68,255089,DB00863,Ranitidine
,1618254,areas under the concentration-time profiles,Mean areas under the concentration-time profiles of ethanol ranged from 83 to 87 mmol.l-1.h for the four treatments.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[h·mM] / [l],83 to 87,255090,DB00863,Ranitidine
,15909533,flow rate,"Samples were eluted with a mobile phase containing acetonitrile-methanol-tetrahydrofuran-20 mM K2HPO4 (pH 7.0) (24:20:10:946, v/v), and the flow rate of the mobile phase was 1 ml/min.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),[ml] / [min],1,256164,DB00863,Ranitidine
,15909533,bile-to-blood distribution ratio (AUC(bile)/AUC(blood)),"The bile-to-blood distribution ratio (AUC(bile)/AUC(blood)) was 9.8 +/- 1.9 and 13.9 +/- 3.8 at the dosages of 10 and 30 mg/kg, respectively.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),,9.8,256165,DB00863,Ranitidine
,15909533,bile-to-blood distribution ratio (AUC(bile)/AUC(blood)),"The bile-to-blood distribution ratio (AUC(bile)/AUC(blood)) was 9.8 +/- 1.9 and 13.9 +/- 3.8 at the dosages of 10 and 30 mg/kg, respectively.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),,13.9,256166,DB00863,Ranitidine
,4041336,systemic clearance,Lignocaine systemic clearance was reduced by 9% (1.11 to 0.99 1 h-1 kg-1; P less than 0.01) following ranitidine pretreatment.,The effect of ranitidine on the disposition of lignocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041336/),[1] / [h·kg],1.11 to 0.99,257423,DB00863,Ranitidine
,4041336,volume of distribution at steady-state,The volume of distribution at steady-state was reduced by 15% (3.34 to 2.85 1 kg-1; P less than 0.005).,The effect of ranitidine on the disposition of lignocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041336/),[1] / [kg],3.34 to 2.85,257424,DB00863,Ranitidine
,3243923,Clearance,Clearance by hemodialysis was 3.0 +/- 1.1 l/hr.,Ranitidine accumulation in patients undergoing chronic hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243923/),[l] / [h],3.0,259572,DB00863,Ranitidine
,3370741,area under the curve,High-dose ranitidine increased the total exposure to doxorubicin (area under the curve of doxorubicin alone = 1.44 +/- 0.88 microM.h/ml vs 4.49 +/- 2.35 microM.hr/ml for doxorubicin given with high-dose ranitidine; P = 0.06).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),[h·μM] / [ml],1.44,259895,DB00863,Ranitidine
,3370741,area under the curve,High-dose ranitidine increased the total exposure to doxorubicin (area under the curve of doxorubicin alone = 1.44 +/- 0.88 microM.h/ml vs 4.49 +/- 2.35 microM.hr/ml for doxorubicin given with high-dose ranitidine; P = 0.06).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),[h·μM] / [ml],4.49,259896,DB00863,Ranitidine
,3370741,half-life,14C-Aminopyrine half-life was altered by a ranitidine dose of 25 mg/kg (aminopyrine half-life after placebo control = 97 +/- 6 min as against aminopyrine half-life after ranitidine = 121 +/- 7 min; mean +/- SEM; P less than 0.02).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),min,97,259897,DB00863,Ranitidine
,3370741,half-life,14C-Aminopyrine half-life was altered by a ranitidine dose of 25 mg/kg (aminopyrine half-life after placebo control = 97 +/- 6 min as against aminopyrine half-life after ranitidine = 121 +/- 7 min; mean +/- SEM; P less than 0.02).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),min,121,259898,DB00863,Ranitidine
,6329583,bioavailability,The bioavailability of ranitidine after oral administration is approximately 50% due to presystemic hepatic metabolism.,Clinical pharmacokinetics of ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6329583/),%,50,260018,DB00863,Ranitidine
,6329583,Plasma protein binding,Plasma protein binding of ranitidine is approximately 15% and the apparent volume of distribution is greater than body volume.,Clinical pharmacokinetics of ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6329583/),%,15,260019,DB00863,Ranitidine
,6329583,elimination half-life,The elimination half-life is almost 2 hours and is somewhat longer after oral administration.,Clinical pharmacokinetics of ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6329583/),h,2,260020,DB00863,Ranitidine
,6329583,Plasma clearance,Plasma clearance is approximately 600 ml/min of which most is renal clearance.,Clinical pharmacokinetics of ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6329583/),[ml] / [min],600,260021,DB00863,Ranitidine
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.25,261184,DB00863,Ranitidine
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.02,261185,DB00863,Ranitidine
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.05,261186,DB00863,Ranitidine
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.13,261187,DB00863,Ranitidine
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.14,261188,DB00863,Ranitidine
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.16,261189,DB00863,Ranitidine
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],10.8,261190,DB00863,Ranitidine
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],12.2,261191,DB00863,Ranitidine
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],12.3,261192,DB00863,Ranitidine
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],90,261193,DB00863,Ranitidine
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],95,261194,DB00863,Ranitidine
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],117,261195,DB00863,Ranitidine
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,0.65,261196,DB00863,Ranitidine
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,1.45,261197,DB00863,Ranitidine
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,0.90,261198,DB00863,Ranitidine
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.04,261199,DB00863,Ranitidine
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.38,261200,DB00863,Ranitidine
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.30,261201,DB00863,Ranitidine
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],16.2,261202,DB00863,Ranitidine
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],14.3,261203,DB00863,Ranitidine
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],13.8,261204,DB00863,Ranitidine
,10586389,maximum serum concentration (Cmax),"Patients were evaluated at steady-state conditions, and the mean maximum serum concentration (Cmax) was 845.7 +/- 448.1 ng/mL.",The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),[ng] / [ml],845.7,261407,DB00863,Ranitidine
,10586389,Cmax,"To adjust for the variable drug dosing used among study patients, both Cmax and area under the concentration curve (AUC) were standardized to dose (CmaxST and AUCST, respectively) and were 217.9 +/- 87.9 ng/mL and 1038.0 +/- 242.2 ng/mL.h.",The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),[ng] / [ml],217.9,261408,DB00863,Ranitidine
,10586389,area under the concentration curve (AUC),"To adjust for the variable drug dosing used among study patients, both Cmax and area under the concentration curve (AUC) were standardized to dose (CmaxST and AUCST, respectively) and were 217.9 +/- 87.9 ng/mL and 1038.0 +/- 242.2 ng/mL.h.",The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),[ng] / [ml],217.9,261409,DB00863,Ranitidine
,10586389,CmaxST,"To adjust for the variable drug dosing used among study patients, both Cmax and area under the concentration curve (AUC) were standardized to dose (CmaxST and AUCST, respectively) and were 217.9 +/- 87.9 ng/mL and 1038.0 +/- 242.2 ng/mL.h.",The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),[ng] / [ml],217.9,261410,DB00863,Ranitidine
,10586389,AUCST,"To adjust for the variable drug dosing used among study patients, both Cmax and area under the concentration curve (AUC) were standardized to dose (CmaxST and AUCST, respectively) and were 217.9 +/- 87.9 ng/mL and 1038.0 +/- 242.2 ng/mL.h.",The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),[ng] / [h·ml],1038.0,261411,DB00863,Ranitidine
,10586389,elimination half-life (t1/2),"The elimination half-life (t1/2) was 2.7 +/- 1.4 hours, and the apparent steady-state volume of distribution (Vdss) was 4.6 +/- 1.7 L/kg.",The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),h,2.7,261412,DB00863,Ranitidine
,10586389,apparent steady-state volume of distribution (Vdss),"The elimination half-life (t1/2) was 2.7 +/- 1.4 hours, and the apparent steady-state volume of distribution (Vdss) was 4.6 +/- 1.7 L/kg.",The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),[l] / [kg],4.6,261413,DB00863,Ranitidine
,10586389,plasma clearance,The plasma clearance was 1.022 +/- 0.290 L/kg/h.,The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586389/),[l] / [h·kg],1.022,261414,DB00863,Ranitidine
,2869002,apparent volume of distribution,The drug was widely distributed with an apparent volume of distribution between 140 and 200 l.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),l,140 and 200,264365,DB00863,Ranitidine
,2869002,plasma clearance,The plasma clearance was between 56 and 69 L/h.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),[l] / [h],56 and 69,264366,DB00863,Ranitidine
,2869002,elimination half-life,The plasma concentrations declined following a monoexponential function with an elimination half-life of 2 h.,"Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869002/),h,2,264367,DB00863,Ranitidine
,1794156,Me,Mesor acid output ranged from 1.7 to 11.6 mmol/h (mean 5.6 +/- 2.8 mmol/h) and the amplitude ranged from 0.7 to 6.5 mmol/h (mean 2.8 +/- 1.6 mmol/h).,Effect of basal gastric acid secretion on the pharmacodynamics of ranitidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794156/),[mM] / [h],5.6,266809,DB00863,Ranitidine
,1794156,amplitude,Mesor acid output ranged from 1.7 to 11.6 mmol/h (mean 5.6 +/- 2.8 mmol/h) and the amplitude ranged from 0.7 to 6.5 mmol/h (mean 2.8 +/- 1.6 mmol/h).,Effect of basal gastric acid secretion on the pharmacodynamics of ranitidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794156/),[mM] / [h],2.8,266810,DB00863,Ranitidine
,1794156,50% inhibitory concentration (IC50),"The 50% inhibitory concentration (IC50) for ranitidine ranged from 10-75 ng/ml, with a mean of 44 ng/ml.",Effect of basal gastric acid secretion on the pharmacodynamics of ranitidine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794156/),[ng] / [ml],44,266811,DB00863,Ranitidine
up to,18465300,encapsulation efficiencies,The formulated microspheres were free flowing with good packability and encapsulation efficiencies were up to 96%.,In vitro and in vivo evaluation of ranitidine hydrochloride ethyl cellulose floating microparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18465300/),%,96,266881,DB00863,Ranitidine
,3964528,volume of the initial dilution space,Values of the volume of the initial dilution space (median = 89 ml kg-1) and volume of distribution at steady state (median = 1.54 l kg-1) were about 60% of corresponding mean literature values for healthy controls.,Pharmacokinetics of ranitidine in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964528/),[ml] / [kg],89,266892,DB00863,Ranitidine
,3964528,volume of distribution at steady state,Values of the volume of the initial dilution space (median = 89 ml kg-1) and volume of distribution at steady state (median = 1.54 l kg-1) were about 60% of corresponding mean literature values for healthy controls.,Pharmacokinetics of ranitidine in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964528/),[l] / [kg],1.54,266893,DB00863,Ranitidine
,3964528,Plasma clearance,"Plasma clearance (median = 4.22 ml min-1 kg-1) and terminal half-life (median = 4.7 h) were about 2-3 fold less and 2-3 fold greater, respectively, than values for healthy controls.",Pharmacokinetics of ranitidine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964528/),[ml] / [kg·min],4.22,266894,DB00863,Ranitidine
,3964528,terminal half-life,"Plasma clearance (median = 4.22 ml min-1 kg-1) and terminal half-life (median = 4.7 h) were about 2-3 fold less and 2-3 fold greater, respectively, than values for healthy controls.",Pharmacokinetics of ranitidine in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3964528/),h,4.7,266895,DB00863,Ranitidine
,10501912,time to maximum plasma concentration (t(max)),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.8,267114,DB00863,Ranitidine
,10501912,elimination half-life (t(1/2)),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.8,267115,DB00863,Ranitidine
,10501912,t(max),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.9,267116,DB00863,Ranitidine
,10501912,t(1/2),Temozolomide was rapidly absorbed [time to maximum plasma concentration (t(max)) 1.8 h] and eliminated [elimination half-life (t(1/2)) 1.8 h] and MTIC followed a similar pattern with a t(max) of 1.9 h and a t(1/2) of 1.9 h.,Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501912/),h,1.9,267117,DB00863,Ranitidine
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,70,269860,DB00863,Ranitidine
,6317740,Systemic bioavailability,Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine.,Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),%,50,269861,DB00863,Ranitidine
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,1.7-2.1,269862,DB00863,Ranitidine
,6317740,elimination half-lives,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),h,2.1-3.1,269863,DB00863,Ranitidine
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,50,269864,DB00863,Ranitidine
,6317740,apparent volumes of distribution,"The elimination half-lives of cimetidine and ranitidine are 1.7-2.1 hours and 2.1-3.1 hours, respectively, with apparent volumes of distribution approximating 50L and 75L, respectively.",Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6317740/),l,75,269865,DB00863,Ranitidine
,4056078,corrected clearance,The apparent plasma clearance did not vary with the increase in dose; and the average corrected clearance values ranged between 6.7 and 10 mL/(min X kg).,Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056078/),[ml] / [kg·min],6.7 and 10,273103,DB00863,Ranitidine
,4056078,Elimination half-life,Elimination half-life was between 2.6 and 3.0 hours; and the volume of distribution (Vd area) was between 1.6 and 2.4 L/kg.,Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056078/),h,2.6 and 3.0,273104,DB00863,Ranitidine
,4056078,volume of distribution (Vd area),Elimination half-life was between 2.6 and 3.0 hours; and the volume of distribution (Vd area) was between 1.6 and 2.4 L/kg.,Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056078/),[l] / [kg],1.6 and 2.4,273105,DB00863,Ranitidine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB00863,Ranitidine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB00863,Ranitidine
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB00863,Ranitidine
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB00863,Ranitidine
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB00863,Ranitidine
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB00863,Ranitidine
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB00863,Ranitidine
,7509380,final elimination half-life,"Taxol plasma concentrations declined in a triexponential fashion, with a final elimination half-life of 10 to 12 hours.",Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7509380/),h,10 to 12,273487,DB00863,Ranitidine
